Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.

Currently viewing trials
(Last updated: March 18, 2023)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

Click here to view online studies and trials that do not require site visits

NEAREST SITE: 22 miles
Contra Costa Regional Medical Center
Martinez,CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT03418961

Carvedilol to Prevent Heart Problems in People with Metastatic HER2+ Breast Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III Scientific Title

Purpose

To investigate whether a beta-blocker can help prevent heart problems caused by cancer treatments.

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+) breast cancer who are receiving or planning to receive trastuzumab (Herceptin®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1: Intervention <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carvedilol, by mouth, daily for up to 2 years</li> </ul> Group 2: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li> </ul> Group 3: If you are already taking taking a beta blocker, ARB, or ACE inhibitor <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Observation for up to 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity. </li> <li class="seamTextUnorderedListItem">The beta-blocker being used in this study is carvedilol. It is used to treat heart failure and high blood pressure.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03418961' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/side_effects/heart_probs' target='_blank'>Breastcancer.org: Heart Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.health.harvard.edu/heart-health/treatments-for-breast-cancer-may-harm-the-heart' target='_blank'>Harvard Health Publishing: Treatments for Breast Cancer</a> </li></ul>

NEAREST SITE: 27 miles
Stanford Cancer Institute
San Francisco,CA

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT05366699

Procedure to Prevent Lymphedema After Lymph Node Removal for Women with Stage I-III Breast Cancer

A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy Scientific Title

Purpose

To determine if immediate lymphatic reconstruction during lymph node removal reduces the risk of developing lymphedema and improves quality of life.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive lymph node removal. You must not have received radiation to the lymph node that will be removed. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Removal of axillary (underarm/armpit) lymph nodes</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Removal of axillary (underarm/armpit) lymph nodes</li> <li class="seamTextUnorderedListItem">Immediate lymphatic reconstruction (LYMPHA) with axillary reverse mapping</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a chronic, progressive, and debilitating condition that occurs with damage to the lymphatic system, which commonly occurs as a result of breast cancer treatment.</li> <li class="seamTextUnorderedListItem">Lymphatic reconstruction (LYMPHA) is when the cut lymphatic vessels are reconnected to your veins.</li> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM) is when a dye is injected into your arm so that your surgeon can see and try to avoid disrupting the lymph nodes and lymphatic channels that drain your arm.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05366699' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/about-your-immediate-lymphatic-reconstruction-ilr-procedure' target='_blank'>Memorial Sloan Kettering Cancer Center: Immediate Lymphatic Reconstruction (ILR)</a> </li><li class='seamTextUnorderedListItem'><a href='https://friedmancenter.org/lymphedema-overview/preventing-lymphedema/' target='_blank'>Friedman Center for Breast and Lymphatic Surgery: LYMPHA Procedure</a> </li><li class='seamTextUnorderedListItem'><a href='https://breast360.org/topic/2017/01/01/axillary-reverse-mapping/' target='_blank'>Breast360.org: Axillary Reverse Mapping</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>

NEAREST SITE: 336 miles
University of California at Los Angeles
Los Angeles,CA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT04297020

Studying the Effects of Anti-Estrogen Therapy on the Brain of Women with Stage I-III Breast Cancer

Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy Scientific Title

Purpose

To see if anti-estrogen therapy affects brain health.

Who is this for?

Women between the ages of 35 and 65 who are currently taking anti-estrogen therapy for stage I, stage II, or stage III breast cancer and who did not receive chemotherapy. This trial is also enrolling women who have never been diagnosed with breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 Brain fMRI (functional MRI)</li> <li class="seamTextUnorderedListItem">Cognitive testing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use an advanced brain MRI technique called functional MRI (fMRI).</li> <li class="seamTextUnorderedListItem">fMRI measures changes in blood flow that happen during mental activity. </li> <li class="seamTextUnorderedListItem">Research suggests that the cognitive issues experienced by some women who receive treatment for breast cancer--also called <q>chemo brain</q>--may actually be caused by anti-estrogen therapy and not chemotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04297020' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medscape.com/viewarticle/932091' target='_blank'>MedScape: In Breast Cancer, Is Chemobrain Really Endocrine Brain?</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Functional_magnetic_resonance_imaging' target='_blank'>Wikipedia: Functional MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=fmribrain' target='_blank'>RadiologyInfo.org: fMRI</a> </li></ul>

NEAREST SITE: 341 miles
Cancer Clinical Trials Office
Los Angeles,CA

VISITS: 8 visits

PHASE: NA

NCT ID: NCT05403736

Improving Heart Heath After Radiation for Stage I-IV Breast Cancer

IIT2021-07-Atkins-CARMA: Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial Scientific Title

Purpose

To hold cardio-oncology consultations during cancer treatment to improve heart health after radiation therapy.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer receiving or planning to receive radiation where the heart is in the treatment field. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardio-oncology consultation, weekly for 6 weeks, then 2 follow-up visits within 5 months</li> <li class="seamTextUnorderedListItem">Wearable devices</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity. </li> <li class="seamTextUnorderedListItem">Cardiologists and cancer doctors will review any cardiovascular risk factors (heart conditions, hypertension, bleeding disorders, smoking history, obesity, cholesterol and diabetes) and develop a personalized treatment plan.</li> <li class="seamTextUnorderedListItem">Wearable devices, such as a FitBit, remote EKG, and remote blood pressure monitoring, will be used to monitor your health.</li> <li class="seamTextUnorderedListItem">Blood will be drawn 3 times for biomarker testing of heart injury, aging, inflammation and metabolism.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05403736' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/17409-radiation-heart-disease-overview' target='_blank'>Cleveland Clinic: Radiation Heart Disease</a> </li></ul>

NEAREST SITE: 341 miles
Cedars Sinai Medical Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04604158

Elly Mobile Application to Reduce Anxiety in People Living With Breast Cancer

IIT2020-13-GRESHAM-ELLY: Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients Scientific Title

Purpose

To study if the Elly iPhone application reduces anxiety, stress, loneliness, and social isolation.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving treatment or have received treatment within the past 6 months. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elly iPhone application</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Elly mobile application delivers daily audio recordings aimed at reducing anxiety, stress, loneliness, and social isolation.</li> <li class="seamTextUnorderedListItem">In this trial, the Elly mobile application is only available on iPhones.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04604158' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ellyhealth.com/' target='_blank'>Elly Health: Elly Mobile App</a> </li></ul>

NEAREST SITE: 348 miles
USC Norris Comprehensive Cancer Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT01802346

Low-Calorie Diet To Reduce Side Effects of Chemotherapy

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of

Who is this for?

Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Participants will be randomly assigned to 1 of 2 groups: Group 1: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eat a special low-calorie diet during before, during and after chemotherapy (All food provided)</li> </ul> Group 2: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eat a normal diet, receive dietary advice from a nutritionist</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01802346' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/chemotherapy/side_effects' target='_blank'>BreastCancer.org: Chemotherapy Side Effects</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-chemotherapy' target='_blank'>Cancer.gov: Chemotherapy</a> </li></ul>

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT05340673

Aquaphor and Miaderm for Radiation Dermatitis

A Randomized Clinical Trial Comparing Supplemental Topical Treatments for Acute Radiation Dermatitis in Breast Cancer Patients Scientific Title

Purpose

To compare the ability of Aquaphor and Miaderm, 2 supplemental topical agents, to treat and prevent radiation dermatitis.

Who is this for?

People with DCIS, stage I, stage II, or stage III breast cancer that are receiving external beam radiation therapy (EBRT) after surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aquaphor, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Miaderm, daily</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation dermatitis is a radiation-induced skin reaction that can cause itching, swelling, pain, and general discomfort.</li> <li class="seamTextUnorderedListItem">Aquaphor and Miaderm are 2 supplemental topical agents commonly recommended and used by people with breast cancer undergoing external beam radiation therapy (EBRT).</li> <li class="seamTextUnorderedListItem">Aquaphor is a commonly available, inexpensive, petrolatum-based multi-purpose ointment designed to protect and sooth extremely dry skin, chapped lips, cracked hands and feet, minor cuts and burns, and many other skin irritations.</li> <li class="seamTextUnorderedListItem">Miaderm is a water-based cream and contains ingredients like calendula, hyaluronate, and aloe vera which may help reduce occurrence and severity of radiation dermatitis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05340673' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21995-radiation-burns#:~:text=Radiation%20burn%20or%20radiation%20dermatitis,peel%2C%20itch%20or%20turn%20red.' target='_blank'>Cleveland Clinic: Radiation Dermatitis</a> </li></ul>

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA

VISITS: May require hospitalization

PHASE: II

NCT ID: NCT05139043

Dexamethasone to Reduce Swelling after Brain Surgery

Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients With Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study. Scientific Title

Purpose

To compare the safety and anti-swelling activity of 2 dose levels of dexamethasone before and after brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, daily for 3 days</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by IV</li> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by IV, daily for 3 days</li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, daily for 2 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery is an important part of the treatment of brain tumors. However, surgery results in injury to surrounding brain tissue and leads to brain swelling.</li> <li class="seamTextUnorderedListItem">Dexamethasone is effective for controlling the swelling of the brain. However, dexamethasone can cause many unwanted side effects.</li> <li class="seamTextUnorderedListItem">To minimize the side effects of dexamethasone, the lowest dose should be used.</li> <li class="seamTextUnorderedListItem">In this trial, you will receive 1 of 2 dose levels of dexamethasone: standard dose or lower dose.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05139043' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 374 miles
University of California Irvine
Orange,CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT03937154

Romiplostim for Low Blood Platelets During Chemotherapy in People with Breast Cancer

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Scientific Title

Purpose

To study the safety and effects (good and bad) of romiplostim (Nplate®) for chemotherapy-induced thrombocytopenia.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving or planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Romiplostim (Nplate®), by injection, 3-6 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for romiplostim (Nplate®), by injection, 3-6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy-induced thrombocytopenia (CIT) is having a low number of blood platelets, which are blood cells that help your blood clot, as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Romiplostim (Nplate®) increases the number of blood platelets to help your blood clot and reduce your risk of bleeding.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03937154' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a609008.html' target='_blank'>MedlinePlus: Romiplostim (Nplate®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/diseases-conditions/thrombocytopenia/symptoms-causes/syc-20378293#:~:text=Thrombocytopenia%20is%20a%20condition%20in,plugs%20in%20blood%20vessel%20injuries.' target='_blank'>Mayo Clinic: Thrombocytopenia</a> </li></ul>

NEAREST SITE: 386 miles
Loma Linda University Cancer Center
Loma Linda,CA

VISITS: 1-2 visits within 1-2 days

PHASE: III

NCT ID: NCT03598426

3 Regimens to Prevent Allergic Reactions to Chemotherapy for Women with Stage I-IV Breast Cancer

Conventional Prophylactic Regimen of Oral Dexamethasone Versus Short-course Intravenous Dexamethasone in Preventing Paclitaxel-related Hypersensitivity Reactions in Breast and Gynecologic Oncology Patients: A Prospective, Randomized, Open-label Study Scientific Title

Purpose

To compare the ability of 3 regimens of dexamethasone, diphenhydramine (Benadryl®), and famotidine to prevent allergic reactions to paclitaxel (Taxol®) chemotherapy.

Who is this for?

Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive paclitaxel (Taxol®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth</li> </ul> followed 1 day later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Diphenhydramine (Benadryl®), by IV</li> <li class="seamTextUnorderedListItem">Famotidine, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by IV</li> <li class="seamTextUnorderedListItem">Diphenhydramine (Benadryl®), by IV</li> <li class="seamTextUnorderedListItem">Famotidine, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth</li> </ul> followed 1 day later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, by IV</li> <li class="seamTextUnorderedListItem">Diphenhydramine (Benadryl®), by IV</li> <li class="seamTextUnorderedListItem">Famotidine, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Dexamethasone, diphenhydramine (Benadryl®), and famotidine are drugs that help prevent allergic reactions to chemotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03598426' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/taxol' target='_blank'>Breastcancer.org: Paclitaxel (Taxol®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a687011.html' target='_blank'>MedlinePlus: Famotidine</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a682792.html' target='_blank'>MedlinePlus: Dexamethasone</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a682539.html' target='_blank'>MedlinePlus: Diphenhydramine (Benadryl®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/allergic' target='_blank'>Breastcancer.org: Allergic Reactions</a> </li></ul>

NEAREST SITE: 414 miles
Nevada Cancer Research Foundation NCORP
Las Vegas,NV

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT03367572

Combinations of Antiemetics for Reducing Chemotherapy-Induced Nausea and Vomiting

Treatment of Refractory Nausea Scientific Title

Purpose

Who is this for?

Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Netupitant/palonosetron hydrochloride, by mouth, within 1 hour prior to receiving chemotherapy, on day 1 </li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, within 30 minutes prior to chemotherapy, days 1-4 </li> <li class="seamTextUnorderedListItem">Placebo, by mouth, every 8 hours with chemotherapy, days 1-4 </li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Netupitant/palonosetron hydrochloride, by mouth, within 1 hour prior to receiving chemotherapy, on day 1 </li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, within 30 minutes prior to chemotherapy, days 1-4 </li> <li class="seamTextUnorderedListItem">Prochlorperazine and placebo, by mouth, every 8 hours with chemotherapy, days 1-4 </li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Netupitant/palonosetron hydrochloride, by mouth, within 1 hour prior to receiving chemotherapy, on day 1 </li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, within 30 minutes prior to chemotherapy, days 1-4 </li> <li class="seamTextUnorderedListItem">Olanzapine and placebo, by mouth, every 8 hours with chemotherapy, days 1-4</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03367572' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/research-news/updated-asco-guidelines-on-antiemetics' target='_blank'>ASCO: Guidelines to treat nausea and vomiting</a> </li></ul>

NEAREST SITE: 447 miles
Moores Cancer Center
San Diego,CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04343157

Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastasis

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of cognitive-sparing stereotactic radiosurgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have at least 1 brain tumor that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive-sparing stereotactic radiosurgery</li> <li class="seamTextUnorderedListItem">MRI scans, 4 scans within 6 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive tests</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Cognitive-sparing stereotactic radiosurgery is a targeted radiation therapy that avoids the white matter and hippocampus (parts of the brain that control memory, language, attention, and cognition).</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04343157' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT

VISITS: 2 visits over 1 week

PHASE: II

NCT ID: NCT02317783

Using Brain Imaging to Study the Effect of Chemotherapy on the Brain

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment Scientific Title

Purpose

To use PET scans to study how chemotherapy affects the brain.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who received chemotherapy after surgery within the last three years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive 2 FDG-PET scans using flutemetamol over a week
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many cancer patients have thinking and memory problems due to cancer or its treatments. The reasons for this <q>mental fog,</q> referred to as chemo brain, are not always known.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02317783' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02317783?term=NCT02317783&rank=1' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/chemotherapyeffects/chemo-brain' target='_blank'>Cancer.org: Chemo Brain</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm' target='_blank'>FDA.gov: Imaging Drug, Flutemetamol</a> </li></ul>

NEAREST SITE: 1500 miles
University of Kansas Medical Center
Kansas City,KS

VISITS: Daily visits for 1 month

PHASE: NA

NCT ID: NCT02958774

Hypofractionated Radiation To Treat Regional Lymph Nodes to Reduce Lymphedema Risk

Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation Scientific Title

Purpose

To learn whether hypofractionated radiation therapy is less likely to cause lymphedema than conventional radiation therapy.

Who is this for?

Women with stage II or stage III breast cancer that has spread to the lymph nodes (node positive) who will be treated with radiation after breast cancer surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypofractionated radiation therapy, daily, for 1 month</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a swelling of the soft tissues in the arm and hand caused by a build-up of lymph fluid. </li> <li class="seamTextUnorderedListItem">Radiation therapy to the lymph nodes can result in scar tissue that blocks the lymph flow, increasing risk for lymphedema. </li> <li class="seamTextUnorderedListItem">Hypofractionated radiation therapy is a type of radiation therapy that is given at a higher dose over a shorter period of time than standard radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02958774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hypofractionated-radiation-therapy' target='_blank'>NCI Dictionary of Cancer Terms: Hypofractionated radiation therapy</a> </li></ul>

NEAREST SITE: 1548 miles
Mary Greeley Medical Center
Ames,IA

VISITS: 1 visit every 3 months for 1.5 years

PHASE: NA

NCT ID: NCT05568472

Monitoring Symptoms to Help Women Continue Taking Hormone Therapy for Stage I-III Breast Cancer

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) Scientific Title

Purpose

To study if reporting symptoms by email, text, or phone helps women continue taking hormone therapy.

Who is this for?

Premenopausal or perimenopausal women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy. You must have received surgery within 2 weeks of beginning this trial. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Receive health education materials</li> <li class="seamTextUnorderedListItem">Attend clinic visits, every 3 months for 1.5 years</li> <li class="seamTextUnorderedListItem">Report symptoms, by email, text, or phone, weekly for 6 months, then monthly for 1 year</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Receive health education materials</li> <li class="seamTextUnorderedListItem">Attend clinic visits, every 3 months for 1.5 years</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy is a common treatment for hormone receptor positive (HR+) breast cancer.</li> <li class="seamTextUnorderedListItem">Hormone therapy can cause side effects which may cause some women to stop treatment early. Asking about symptoms may help women continue taking hormone therapy.</li> <li class="seamTextUnorderedListItem">Health education materials contain information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health.</li> <li class="seamTextUnorderedListItem">Questionnaires can be completed in English or Spanish.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women will also be given a drug that will put women in temporary menopause.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05568472' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20070906b' target='_blank'>Breastcancer.org: Side Effects of Hormone Therapy</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT03428581

Two Surgical Techniques to Prevent Lymphedema in Women Having a Lymph Node Dissection

Preventing Lymphedema in Patients Undergoing Axillary Lymph Node Dissection Via Axillary Reverse Mapping and Lympho-venous Bypass Scientific Title

Purpose

To see if using two surgical techniques during surgery to remove lymph nodes from your underarm area (axillary lymph node dissection) prevents lymphedema.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who will be having an axillary lymph node dissection (ALND). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups and receive the following: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary lymph node dissection (ALND)</li> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM), during the ALND</li> <li class="seamTextUnorderedListItem">Lymphovenous bypass, during the ALND</li> </ul> Group 2: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary lymph node dissection (ALND)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that may develop as a side effect of some breast cancer surgeries.</li> <li class="seamTextUnorderedListItem">Lymphedema happens when there is a blockage in your lymphatic system (a part of your immune system) that stops the lymph fluid from draining well. The fluid buildup causes the abnormal swelling.</li> <li class="seamTextUnorderedListItem">The surgery that removes lymph nodes from your underarm area is called an axillary lymph node dissection (ALND).</li> <li class="seamTextUnorderedListItem">Axillary Reverse Mapping (ARM) is when a dye is injected into your arm so that your surgeon can see and try to avoid disrupting the lymph nodes and lymphatic channels that drain your arm. </li> <li class="seamTextUnorderedListItem">Lymphovenous bypass is when your surgeon connects some of your lymphatic channels directly into tiny veins in your arm.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03428581' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20359609' target='_blank'>Mayo Clinic: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/lymph_node_removal/axillary_dissection' target='_blank'>Breastcancer.org: Axillary Lymph Node Dissection (ALND)</a> </li><li class='seamTextUnorderedListItem'><a href='https://breast360.org/topic/2017/01/01/axillary-reverse-mapping/' target='_blank'>Breast360.org: Axillary Reverse Mapping (ARM)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/about-your-lymphovenous-bypass-lvb-surgery-lymphedema' target='_blank'>Memorial Sloan Kettering Cancer Center: About Your Lymphovenous Bypass (LVB) Surgery for Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/plastic_reconstructive_surgery/services-appts/lymphedema.html' target='_blank'>Johns Hopkins Medicine: Surgical Treatment of Lymphedema</a> </li></ul>

NEAREST SITE: 1643 miles
Houston Methodist Cancer Center
Houston,TX

VISITS: 4 visits, over 6 months

PHASE: II

NCT ID: NCT01984138

Hormone Therapy or Lotion Inside the Vagina for Women with Stage I-III ER+ Breast Cancer Taking an Aromatase Inhibitor (Anti-Estrogen Therapy)

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Scientific Title

Purpose

To compare the safety and effects of using vaginal estrogen (Estring) or a vaginal moisturizer (Replens) to treat vaginal dryness, pain during intercourse, and other vaginal side effects of taking an aromatase inhibitor.

Who is this for?

Postmenopausal women with stage I, stage II, or stage III estrogen-receptor positive (ER+) breast cancer experiencing vaginal dryness, pain during intercourse, or 3 or more urinary tract infections a year since starting an aromatase inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estring vaginal ring, inserted into the vagina, every 3 months, for 6 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Replens vaginal lotion, applied inside the vagina, 3 times a week, for 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of anti-estrogen therapy commonly used for stage I-IV hormone-positive (ER+ and/or PR+) breast cancer. </li> <li class="seamTextUnorderedListItem">The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">The side effects of taking an aromatase inhibitor may include vaginal dryness, vaginal itching, pain during intercourse, and urinary tract infections. </li> <li class="seamTextUnorderedListItem">Replens is a moisturizer that is applied inside the vagina. It does not contain any hormones.</li> <li class="seamTextUnorderedListItem">Estring is a ring that is placed inside the vagina and releases a low dose of estrogen.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01984138' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.houstonmethodist.org/1285_houstonmethodist/2847_ourresearch/2922_research_clinicaltrials/2923_research_searchclinicaltrials/clinicaltrialdetailnew/?Id=Pro00017710' target='_blank'>Houston Methodist Medical Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.estring.com/vaginal-atrophy-relief#estring' target='_blank'>Pfizer Drug Information Page: Estring (Vaginal Estrogen)</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.replens.com/Products/Replens-Long-Lasting-Moisturizer/FAQS.aspx' target='_blank'>Replens Drug Information Page: Replens (Vaginal Moisturizer)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/tips/menopausal/treat/vaginal-changes' target='_blank'>Breastcancer.org: Menopause Symptoms and Vaginal Changes</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 10-12 visits over 8 weeks

PHASE: II

NCT ID: NCT02754752

Acupuncture for Relieving Severe Post-Mastectomy Pain

Randomized-Controlled Trial of Acupuncture for Post-Mastectomy Pain Syndrome Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of

Who is this for?

Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1: Acupuncture on specific body points <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 10 acupuncture sessions, over 4 weeks</li> <li class="seamTextUnorderedListItem">6 Questionnaires, over 8 weeks</li> </ul> Group 2: Acupuncture on non-specific body points <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 10 acupuncture sessions, over 4 weeks</li> <li class="seamTextUnorderedListItem">6 Questionnaires, over 8 weeks</li> </ul> Group 3: Wait-List <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No acupuncture</li> <li class="seamTextUnorderedListItem">After 4 weeks, optional participation in up to 10 acupuncture sessions, over 4 weeks</li> <li class="seamTextUnorderedListItem">6 Questionnaires, over 8 weeks</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02754752' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/pain/post-mastectomy-pain-syndrome.html' target='_blank'>American Cancer Society: Post-mastectomy Pain Syndrome</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 5 visits within 3 months

PHASE: I

NCT ID: NCT04038619

Fecal Microbiota Transplantation for Immunotherapy-Related Diarrhea or Colitis in People with Stage I-IV Breast Cancer

Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients Scientific Title

Purpose

To study the ability of a fecal microbiota transplantation to improve immune checkpoint inhibitor-related diarrhea and colitis.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who developed diarrhea and/or colitis after receiving treatment with dostarlimab (Jemperli®) or pembrolizumab (Keytruda®) immune checkpoint inhibitors. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Loperamide, by mouth, 1 time</li> </ul> followed 4 hours later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fecal microbiota transplantation during colonoscopy, 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A fecal microbiota transplantation consists of taking healthy bacteria (microbiota) from the feces or stool of a healthy donor and transferring them to the colon of the recipient during a colonoscopy.</li> <li class="seamTextUnorderedListItem">A colonoscopy is a procedure in which a flexible camera is inserted through the anus to examine the colon/intestines.</li> <li class="seamTextUnorderedListItem">Loperamide is a drug used to treat diarrhea.</li> <li class="seamTextUnorderedListItem">Colitis is inflammation of the colon/intestines.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04038619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0663.html' target='_blank'>MD Anderson Cancer Center: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/fecal-transplant' target='_blank'>Johns Hopkins Medicine: Fecal Microbiota Transplantation</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a682280.html' target='_blank'>MedlinePlus: Loperamide</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy' target='_blank'>Breastcancer.org: Immune Checkpoint Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li></ul>

NEAREST SITE: 1655 miles
University of Iowa Hospitals and Clinics
Iowa City,IA

VISITS: Weekly visits for 3 months

PHASE: II

NCT ID: NCT03642990

Vitamin B3 to Reduce Paclitaxel-Related Peripheral Neuropathy in Metastatic Breast Cancer

Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy Scientific Title

Purpose

To determine whether nicotinamide riboside (Niagen®) prevents the progression of peripheral neuropathy.

Who is this for?

People with stage IV metastatic breast cancer that is being treated with paclitaxel (Taxol®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nicotinamide Riboside (Niagen®), by mouth, twice daily for 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nicotinamide riboside (NR) is a vitamin B3 supplement. </li> <li class="seamTextUnorderedListItem">Studies suggest it may help prevent or treat nerve pain. </li> <li class="seamTextUnorderedListItem">Neuropathy--pain or numbness in the hands and feet--is a type of nerve pain. </li> <li class="seamTextUnorderedListItem">It is a common side effect of certain types of chemotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03642990' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li><li class='seamTextUnorderedListItem'><a href='https://medcom.uiowa.edu/theloop/news/nicotinamide-riboside-vitamin-b3-prevents-nerve-pain-caused-by-cancer-drugs' target='_blank'>University of Iowa: Nicotinamide riboside (vitamin B3) prevents nerve pain caused by cancer drugs</a> </li></ul>

NEAREST SITE: 1678 miles
UW Health Oncology Clinics
Madison,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05609435

REASSURE Follow-Up Care After Treatment for Stage I HR+, HER2- Breast Cancer

Evaluating a Novel Follow-up Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer Survivors in Wisconsin Scientific Title

Purpose

To study whether REASSURE follow-up care improves survivors' preparedness for survivorship.

Who is this for?

Women with stage I hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer diagnosed between 6 months and 2 years ago who have completed treatment. You must not have received chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">REASSURE follow-up care</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care follow-up care</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">REASSURE follow-up care is comprised of three components: 1) the REASSURE patient-reported outcome (PRO) questionnaire to assess your symptoms/concerns, 2) a recommendation for or against a follow-up visit based on your symptoms/concerns, and 3) REASSURE survivorship messaging, including reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps you can take to reduce cancer risk.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05609435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/cancer-types/breast-cancer/follow-care-and-monitoring#:~:text=Your%20follow%2Dup%20care%20may,treated%20for%20curable%20breast%20cancer.' target='_blank'>ASCO: Breast Cancer Follow-up Care and Monitoring</a> </li></ul>

NEAREST SITE: 1678 miles
University of Wisconsin School of Medicine and Public Health
Madison,WI

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT05094102

OnLume Imaging System to Visualize Lymph Nodes During Surgery for Stage I-III Breast Cancer

Intraoperative Evaluation of Axillary Lymphatics for Breast Cancer Patients Undergoing Axillary Surgery Scientific Title

Purpose

To study the ability of the OnLume Imaging System to visualize lymph nodes during lymph node surgery.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning on receiving an axillary lymph node dissection (ALND) or sentinel lymph node (SLN) biopsy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM) with OnLume Imaging System</li> <li class="seamTextUnorderedListItem">Isosulfan blue dye</li> <li class="seamTextUnorderedListItem">Indocyanine green (ICG)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM) with the OnLume Imaging System may improve identification and visualization of lymph nodes, which would improve lymphatic draining of the upper arm during axillary dissection (AD) or sentinel lymph node (SLN) biopsy, thereby reducing the risk of arm lymphedema.</li> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM) is a standard of care procedure in which a surgeon injects a dye into your arm to see and try to avoid disrupting the lymph nodes and lymphatic channels that drain your arm.</li> <li class="seamTextUnorderedListItem">Axillary reverse mapping (ARM) is completed during an axillary lymph node dissection (ALND) or sentinel lymph node (SLN) biopsy.</li> <li class="seamTextUnorderedListItem">During surgery, isosulfan blue dye and indocyanine green (ICG) dyes will be used to see your lymph nodes and the lymphatic channels that drain your arm.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05094102' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onlume.com/technology/' target='_blank'>OnLue Surgical Information Page: OnLume Imaging System</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/lymph-node-removal' target='_blank'>Breastcancer.org: Lymph Node Removal</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/lymph-node-removal/axillary-dissection' target='_blank'>Breastcancer.org: Axillary Lymph Node Dissection</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>

NEAREST SITE: 1827 miles
Northwestern Memorial HealthCare, Central DuPage Hospital, Warrenville Cancer Center
Winfield,IL

VISITS: 10 visits within 2 weeks

PHASE: I

NCT ID: NCT05417282

MW151 and Hippocampal-Avoidant Whole Brain Radiation Therapy for Brain Metastasis

Safety and Tolerability of MW151 Administered With Hippocampal Avoidant Whole Brain Radiation Therapy (HA-WBRT) in Patients With Brain Metastases Scientific Title

Purpose

To study the safety, effects (good and bad), anti-cancer activity, and cognitive effects of MW151, an experimental drug, with hippocampal-avoidant whole brain radiation therapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who have not received whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MW151, by mouth, daily for 1 month</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hippocampal-avoidant whole brain radiation therapy, 10 days within 2 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for MW151, by mouth, daily for 1 month</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hippocampal-avoidant whole brain radiation therapy, 10 days within 2 weeks</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive tests</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MW151 is an experimental drug that may reduce brain inflammation and improve cognitive function.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) treats the entire brain, even tumors that may be too small to see with an MRI.</li> <li class="seamTextUnorderedListItem">Hippocampal avoidance whole brain radiation therapy (HA-WBRT) is a targeted radiation therapy that avoids the hippocampus (part of the brain that controls learning and memory) during radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05417282' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1832 miles
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee,WI

VISITS: Daily for 10 days

PHASE: II

NCT ID: NCT05045950

Memantine for Cognition with Whole Brain Radiation Therapy for Brain Metastasis

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases Scientific Title

Purpose

To study the effects (good and bad) of memantine and whole brain radiation therapy (WBRT) on your cognition (ability to think).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) with pulsed reduced dose rate (PRDR), daily for 10 days</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive testing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li> <li class="seamTextUnorderedListItem">WBRT with pulsed reduced dose rate (PRDR) uses a slower rate of radiation to improve safety and anti-cancer activity.</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®) is a medication that treats cognition (ability to think).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05045950' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-77932-377/memantine-oral/memantine-oral/details' target='_blank'>WebMD: Memantine</a> </li></ul>

NEAREST SITE: 1832 miles
Medical College of Wisconsin
Milwaukee,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03824145

Every Day Counts Lifestyle Program to Improve Quality of Life for Women with Metastatic Breast Cancer

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer Scientific Title

Purpose

To study whether the Every Day Counts lifestyle program improves the quality of life of women with metastatic breast cancer.

Who is this for?

Women with metastatic (stage IV) breast cancer that is currently stable and who live in Milwaukee, Wisconsin or Chicago, Illinois. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Every Day Counts lifestyle program, 4 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Home/work organization intervention, 4 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Every Day Counts lifestyle program promotes nutritional and physical activity changes based on the American Cancer Society nutrition and physical activity guidelines.</li> <li class="seamTextUnorderedListItem">The Every Day Counts lifestyle program consists of: 1) a curriculum binder covering weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 16-weeks, with in-person or virtual supervised exercise sessions and telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to cooking classes emphasizing plant-based eating.</li> <li class="seamTextUnorderedListItem">The home/work organization intervention consists of: 1) a book with overview of home/work organization program with 16 weekly topics with an overview of each chapter, 2) virtual or weekly phone calls with a home organization coach with standard prompts, 3) text messages supporting home/work organization.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03824145' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention/guidelines.html' target='_blank'>American Cancer Society: Guideline for Diet and Physical Activity</a> </li></ul>

NEAREST SITE: 1832 miles
Froedtert Hospital
Milwaukee,WI

VISITS: 1 visit

PHASE: II

NCT ID: NCT03571334

Botulinum Toxin A for Nerve Pain Caused by Chemotherapy in People with Breast Cancer

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy Scientific Title

Purpose

To study the safety and ability of incobotulinumtoxinA (INA) (Xeomin®) to treat chemotherapy induced peripheral neuropathy (CIPN).

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have chemotherapy induced peripheral neuropathy (CIPN). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IncobotulinumtoxinA (INA) (Xeomin®), by injections into hands or feet, 1 time</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Saline water, by injections into hands or feet, 1 time</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, 5 times within 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy induced peripheral neuropathy (CIPN) is nerve pain in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">IncobotulinumtoxinA (INA) (Xeomin®) may help treat nerve pain by inhibiting parts of the pain signaling pathway.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03571334' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/peripheral-neuropathy/what-is-peripherial-neuropathy.html' target='_blank'>American Cancer Society: Chemotherapy Induced Peripheral Neuropathy (CIPN)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-154593/xeomin-intramuscular/details' target='_blank'>WebMD: IncobotulinumtoxinA (INA) (Xeomin®)</a> </li></ul>

NEAREST SITE: 1853 miles
University of Illinois Chicago
Chicago,IL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05259410

Time Restricted Eating During Chemotherapy for Women with Stage I-III Breast Cancer

The Safety and Efficacy of Time Restricted Eating Combined With Chemotherapy During Breast Cancer Treatment Scientific Title

Purpose

To study whether time restricted eating during chemotherapy improves treatment-related outcomes and quality of life and limits treatment-related side effects and weight gain.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy after surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Time restricted eating, 3 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No time restricted eating, 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Time restricted eating, a form of intermittent fasting, is eating all food within the hours of 10:00am and 6:00pm, with water fasting the remaining hours of the day.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05259410' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/intermittent-fasting-may-help-cancer-treatments-work-better' target='_blank'>Breastcancer.org: Intermittent Fasting May Help Cancer Treatments Work Better</a> </li></ul>

NEAREST SITE: 1854 miles
AMITA Health Saint Joseph Chicago
Chicago,IL

VISITS: Coincides with surgery

PHASE: II

NCT ID: NCT05554211

Tranexamic Acid to Reduce Drainage After Bilateral Mastectomy

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage Scientific Title

Purpose

To study the safety and ability of tranexamic acid to reduce drainage after a bilateral mastectomy.

Who is this for?

Women who are planning to receive a bilateral mastectomy to reduce their risk of developing breast cancer and women with DCIS, stage I, stage II, or some stage III breast cancer who are planning to receive a bilateral mastectomy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tranexamic acid, by skin</li> <li class="seamTextUnorderedListItem">Gentamicin</li> </ul> Group 2: Standard Treatment <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo (saline) for tranexamic acid, by skin</li> <li class="seamTextUnorderedListItem">Gentamicin</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A bilateral mastectomy is surgery to remove both breasts.</li> <li class="seamTextUnorderedListItem">Women with a strong family history of breast cancer or a BRCA mutation may choose to undergo a bilateral mastectomy to reduce their risk of developing breast cancer.</li> <li class="seamTextUnorderedListItem">Drains help remove fluid build up in the area where the breast is removed.</li> <li class="seamTextUnorderedListItem">Tranexamic acid is an FDA approved drug that promotes blood clotting by preventing the breakdown of blood clots that your body naturally forms.</li> <li class="seamTextUnorderedListItem">Tranexamic acid is commonly used to control bleeding in a variety of surgeries and is available in injection or oral forms. However, because it is not currently FDA approved for use in elective breast surgery, this drug is considered experimental in this study. </li> <li class="seamTextUnorderedListItem">Gentamicin is an antibiotic used to prevent infection after surgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05554211' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://moffitt.org/cancers/breast-cancer/treatment/bilateral-mastectomy/' target='_blank'>Moffitt Cancer Center: Bilateral Mastectomy</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a612021.html' target='_blank'>Medline Plus: Tranexamic Acid</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verywellhealth.com/managing-your-surgical-drains-following-breast-surgery-4021630' target='_blank'>Verywell Health: Surgical Drains After Breast Surgery</a> </li></ul>

NEAREST SITE: 1857 miles
University of Chicago
Chicago,IL

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03238976

Nature Sounds to Reduce Pain and Anxiety During a Breast Core Needle Biopsy

Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy: A Randomized Study Scientific Title

Purpose

To investigate the effects (good and bad) playing continuous nature sounds during a core needle biopsy has on a patient's pain and anxiety.

Who is this for?

Women scheduled to have a breast core needle biopsy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive continuous nature sounds during core needle biopsy</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive supportive dialogue during core needle biopsy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A core needle biopsy is a procedure that removes a small amount of suspicious tissue from the breast with a needle.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03238976' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/CoreNeedleBiopsy.html' target='_blank'>Susan G. Komen: Core Needle Biopsy</a> </li></ul>

NEAREST SITE: 1857 miles
The University of Chicago Biological Sciences Division/University of Chicago Medical Center
Chicago,IL

VISITS: 1 visit that coincides with surgery

PHASE: NA

NCT ID: NCT04606030

Using a Biobridge Scaffold During Lymphedema Surgery

LymphBridge: Prospective Evaluation of the BioBridge Scaffold as an Adjunct to Lymph Node Transplant for Upper Extremity Lymphedema Scientific Title

Purpose

To investigate the safety and effects (good and bad) of using an experimental device called a Biobridge scaffold during surgery to treat lymphedema.

Who is this for?

People who have completed breast cancer treatment at least three years ago, have no evidence of disease, and have been diagnosed with lymphedema. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vascularized Lymph Node Transplant surgery (VLNT) </li> <li class="seamTextUnorderedListItem">BioBridge Collagen Matrix inserted into your body during surgery </li> </ul> Group 2: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vascularized Lymph Node Transplant surgery (VLNT)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that may develop as a side effect of some breast cancer therapies. </li> <li class="seamTextUnorderedListItem">Lymphedema happens when there is a blockage in your lymphatic system (a part of your immune system) that stops the lymph fluid from draining well. The fluid buildup causes the abnormal swelling. </li> <li class="seamTextUnorderedListItem">The surgery used in this trial to help with your lymphedema is called a vascularized lymph node transfer.</li> <li class="seamTextUnorderedListItem">Your doctor will insert a Biobridge scaffold during your vascularized lymph node transfer. </li> <li class="seamTextUnorderedListItem">The Biobridge scaffold is made of collagen and may help lymph vessels grow around lymph blockages.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04606030' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/breast-cancer-lymphedema-after-treatment' target='_blank'>Johns Hopkins Medicine: Breast Cancer, Lymphedema After Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://intermountainhealthcare.org/services/cancer-care/treatments-and-procedures/lymphedema-treatment/our-services/vascularized-lymph-node-transfer/' target='_blank'>Intermountain Healthcare: Vascularized Lymph Node Transfer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fibralignbio.com/biobridge-2/' target='_blank'>Fibralign Corporation Medical Device Information Page: Biobridge</a> </li></ul>

NEAREST SITE: 1984 miles
James Graham Brown Cancer Center
Louisville,KY

VISITS: 1 visit every 3 weeks

PHASE: II

NCT ID: NCT04990921

Palliative Radiation and Immunotherapy for Metastatic Breast Cancer

A Phase 2 Study of Palliative Radiation in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of stereotactic radiation with pembrolizumab (Keytruda®) immunotherapy.

Who is this for?

Women with stage IV (metastatic) breast cancer who have received at least 2 lines of therapy, including 1 line of chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation, 1-5 sessions</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Palliative radiation reduces side effects of metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04990921' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncolink.org/support/hospice-and-palliative-care/palliative-radiation-treatment#:~:text=Palliative%20radiation%20is%20the%20use,doses)%20than%20traditional%20radiation%20treatment.' target='_blank'>OncoLink: Palliative Radiation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>

NEAREST SITE: 2054 miles
University of Michigan Rogel Cancer Center
Ann Arbor,MI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04827446

Lighting Intervention to Reduce Cancer-Related Fatigue After Treatment for Stage I-III Breast Cancer

A Randomized Trial Of The SYNC APP Scientific Title

Purpose

To study the ability of light interventions on the SYNC app to reduce cancer-related fatigue, sleep, and quality of life.

Who is this for?

People with stage I, stage II, or stage III breast cancer who have completed treatment at least 3 months ago. You must be experiencing fatigue and own an iPhone. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear Apple Watch or Fitbit wearable device, 3 months</li> <li class="seamTextUnorderedListItem">Wear blue-blocking glasses when instructed</li> <li class="seamTextUnorderedListItem">Complete light interventions on SYNC app</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear Apple Watch or Fitbit wearable device, 3 months</li> <li class="seamTextUnorderedListItem">Wear clear glasses when instructed</li> <li class="seamTextUnorderedListItem">Complete light interventions on placebo SYNC app</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fatigue is a major problem for people with cancer that can persist long after treatment ends. </li> <li class="seamTextUnorderedListItem">Recent research has demonstrated that light therapy may reduce fatigue levels in people with cancer during and after treatment.</li> <li class="seamTextUnorderedListItem">A wearable device, such as the Apple Watch and Fitbit, is device you wear that tracks your physical activity.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04827446' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-10663&loc=0&ni=10&pn=533&rl=1' target='_blank'>National Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fatigue/what-is-cancer-related-fatigue.html' target='_blank'>American Cancer Society: Cancer-Related Fatigue</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05503251

Improving Quality of Life and Cognitive Function After Radiation Therapy for People with Brain Metastases

Effect of Early Integrated Neuropsychological Care in Patients With Brain Metastases - A Phase 2 Randomized Controlled Trial Scientific Title

Purpose

To study if neuropsychological evaluations can improve quality of life or cognitive function after radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. You must not have previously received whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropsychological evaluations, 3 times within 6 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No neuropsychological evaluations</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Quality of life refers to the overall enjoyment of life. It holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.</li> <li class="seamTextUnorderedListItem">Neuropsychological evaluation is used to examine the cognitive (thinking) consequences of brain damage, brain disease, and severe mental illness.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05503251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: 1 visit every 1-2 weeks for 1-2 months

PHASE: II-III

NCT ID: NCT04862585

Safely Stopping Pre-Medications During Chemotherapy for Breast Cancer

Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized Trial Scientific Title

Purpose

To study the safety and side effects of stopping pre-medications during treatment with paclitaxel (Taxol®).

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive chemotherapy. You must not have received paclitaxel (Taxol®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every 1-2 weeks, 4 sessions</li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth or IV</li> <li class="seamTextUnorderedListItem">Diphenhydramine, by mouth or IV</li> <li class="seamTextUnorderedListItem">Famotidine (Pepcid®), ranitidine, or cimetidine (Tagamet®), by mouth or IV</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every 1-2 weeks, 2 sessions</li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth or IV</li> <li class="seamTextUnorderedListItem">Diphenhydramine, by mouth or IV</li> <li class="seamTextUnorderedListItem">Famotidine (Pepcid®), ranitidine, or cimetidine (Tagamet®), by mouth or IV</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every 1-2 weeks, 2 sessions</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug that blocks cancer cell growth by stopping cell division which kills cancer cells.</li> <li class="seamTextUnorderedListItem">Pre-medications help prevent paclitaxel (Taxol®) side effects.</li> <li class="seamTextUnorderedListItem">Pre-medications include: dexamethasone, diphenhydramine, famotidine (Pepcid®), ranitidine, and cimetidine (Tagamet®).</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will stop taking pre-medications after your second paclitaxel (Taxol®) dose.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04862585' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/taxol' target='_blank'>Breastcancer.org: Paclitaxel (Taxol®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncologynurseadvisor.com/home/departments/ask-a-pharmacist/importance-of-sequence-in-administering-premeds-with-paclitaxel/#:~:text=Premedications%20are%20administered%20prior%20to,severity%20of%20infusion%2Drelated%20reactions.' target='_blank'>Oncology Nurse Advisor: Paclitaxel (Taxol®) Pre-Medications</a> </li></ul>

NEAREST SITE: 2137 miles
Emory University Hospital Midtown
Atlanta,GA

VISITS: 1 visit every day for 2 weeks

PHASE: NA

NCT ID: NCT05368428

Transcutaneous Electrical Nerve Stimulation for Chemotherapy Induced Peripheral Neuropathy in People with Stage I-III Breast Cancer

Single-Institution Trial Investigating the Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) in Taxane Induced Peripheral Neuropathy (CIPN) in Patients With Early Stage Breast Cancer Scientific Title

Purpose

To determine if transcutaneous electrical nerve stimulation (TENS) reduces chemotherapy induced peripheral neuropathy (CIPN).

Who is this for?

People with stage I, stage II, or stage III breast cancer who are receiving chemotherapy and have chemotherapy induced peripheral neuropathy (CIPN). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transcutaneous electrical nerve stimulation (TENS), daily for 2 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy induced peripheral neuropathy (CIPN) is nerve pain in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Transcutaneous electrical nerve stimulation (TENS) involves mild electric currents applied to some areas of your skin to potentially improve neuropathy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05368428' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/treatments/15840-transcutaneous-electrical-nerve-stimulation-tens' target='_blank'>Cleveland Clinic: Transcutaneous Electrical Nerve Stimulation (TENS)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li></ul>

NEAREST SITE: 2264 miles
Magee Womens Hospital
Pittsburgh,PA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04983342

Apollo Wearable Device to Reduce Fatigue and Pain for People with Metastatic Breast Cancer

Apollo Device for Fatigue in Metastatic Breast Cancer Scientific Title

Purpose

To study if the Apollo wearable device can reduce fatigue and pain.

Who is this for?

Women with metastatic (stage IV) breast cancer who experience fatigue. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Apollo wearable device</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Apollo is a wearable device, similar to a FitBit, that emits vibrations.</li> <li class="seamTextUnorderedListItem">Apollo vibrations activate touch receptors in your skin that are perceived as safety signals by your brain to decrease stress and improve recovery, focus, and energy.</li> <li class="seamTextUnorderedListItem">Apollo is about the size of an Apple watch and can be worn on your ankle, wrist, or arm with two adjustable fabric straps.</li> <li class="seamTextUnorderedListItem">Fatigue is feeling tired.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04983342' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://apolloneuro.com/' target='_blank'>Apollo Neuroscience: Apollo Device</a> </li></ul>

NEAREST SITE: 2265 miles
UPMC Hillman Cancer Center
Pittsburgh,PA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05314179

Doulas for Black Women with Metastatic Breast Cancer at the End of Life

Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community (Doulas - AC) Scientific Title

Purpose

To provide a doula to journey alongside Black women with metastatic breast cancer, explore meaning and create legacy, offer support and navigation, and provide support and connection for family/friends.

Who is this for?

Black women with stage IV (metastatic) breast cancer who live in the Pittsburgh, Pennsylvania area. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visits from a doula, 5 hours per week</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A doula is a community-based, trained non-medical professional outside of the hospital staff and social circle who will provide you individual physical, emotional, and informational support through metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Doulas will help women explore meaning and create legacy, offer support and navigation for practical needs such as financial assistance for food and housing, accessing and affording medications, and transportation, and provide support for bereaved family/friends.</li> <li class="seamTextUnorderedListItem">A weekly plan will be implemented by the doula which may involve conversations, creating legacy projects, conversations with family and patients, and assistance with practical issues.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05314179' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ctsi.pitt.edu/funding/funding-opportunities/pitt-innovation-challenge-pinch/pitt-innovation-challenge-2021/doulas-ac/' target='_blank'>University of Pittsburgh (Video and Article): Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.palcare.pitt.edu/studies/dignity-legacy-advocacy-and-support-for-individuals-with-advanced-cancer-doulas-ac/' target='_blank'>University of Pittsburgh: Trial Information Page</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03679559

Three Month Exercise Program for People with Stage I-III Breast Cancer Who Have Completed Treatment

Exercise to Improve Health and Quality-of-Life in Breast Cancer Survivors: A Feasibility Pilot Trial Scientific Title

Purpose

To study and compare how different exercise programs affect health and quality of life.

Who is this for?

People diagnosed with stage I, stage II, or stage III breast cancer who have completed treatment--though you can still enroll if you are currently taking anti-hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 4 groups and receive the following: Group 1: Walking and resistance training <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking sessions tracked by a Fitbit, 30 minutes a day, 5 days a week, for 3 months </li> <li class="seamTextUnorderedListItem">Resistance training sessions using a training DVD and TheraBand exercise bands, 6 times over 3 months</li> </ul> Group 2: Zumba and resistance training <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zumba or other classes on an XBOX while wearing a Fitbit, 50 minutes a day, 3 days a week, for 3 months</li> <li class="seamTextUnorderedListItem">Resistance training sessions using a training DVD and TheraBand exercise bands, 6 times over 3 months</li> </ul> Group 3: HIIT and resistance training <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Supervised HIIT sessions while wearing a Fitbit, 3 days a week, for 3 months</li> <li class="seamTextUnorderedListItem">Resistance training sessions using a training DVD and TheraBand exercise bands, 6 times over 3 months</li> </ul> Group 4: Usual physical activity <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will wear a Fitbit to monitor your physical activity, for 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Research suggests that regular exercise decreases fatigue in breast cancer survivors and generally improves quality of life.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03679559' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fredhutch.org/en/news/center-news/2014/06/breast-cancer-patients-exercise.html' target='_blank'>Fred Hutchinson Cancer Research Center: Most Breast Cancer Patients Don't Get Enough Exercise</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/breast-cancer-survival-exercise' target='_blank'>NCI Cancer Currents Blog: Exercise and Survival for Women with Breast Cancer</a> </li></ul>

NEAREST SITE: 2314 miles
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03987555

Studying the Amount of Chemotherapy in the Blood in People with Breast Cancer

Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Scientific Title

Purpose

To study the ability of researchers to measure the amount of paclitaxel (Taxol®) in blood and study the effect of paclitaxel (Taxol®) on neuropathy.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive treatment with paclitaxel (Taxol®) at Wake Forest Comprehensive Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Surveys about neuropathy</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Nerve damage is one of the most common and severe side effects of paclitaxel (Taxol®).</li> <li class="seamTextUnorderedListItem">The ability to consistently measure paclitaxel (Taxol®) in the blood may allow doctors to control the dose of paclitaxel, so that enough chemotherapy is given to kill the cancer, but the side effect of nerve damage is reduced.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03987555' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/paclitaxel-taxol' target='_blank'>Breast Cancer Now: Paclitaxel (Taxol®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li></ul>

NEAREST SITE: 2351 miles
University of Florida
Gainesville,FL

VISITS: 1 visit every 1-3 weeks for 3 months

PHASE: I-II

NCT ID: NCT05074290

Epidiferphane Nutritional Supplement with Chemotherapy for Stage I-IV Breast Cancer

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients Scientific Title

Purpose

To study the safety, best dose, effects (good and bad), and anti-cancer activity of epidiferphane, an experimental nutritional supplement, with chemotherapy.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning on receiving treatment with chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane, by mouth, daily for 3 months</li> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Docetaxel (Taxotere®), every 3 weeks; paclitaxel (Taxol®), weekly; or nab-paclitaxel (Abraxane®), weekly; 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Epidiferphane is an experimental nutritional supplement that may reduce chemotherapy symptoms.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), paclitaxel (Taxol®), and nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with lobular breast cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05074290' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epidiferphane' target='_blank'>National Cancer Institute: Epidiferphane</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

NEAREST SITE: 2352 miles
University of Rochester Medical Center
Rochester,NY

VISITS: At least 8 visits

PHASE: NA

NCT ID: NCT04230941

MAAT-G Workshops and Workbook to Improve Cognition for People Ages 65+ With Breast Cancer After Completing Treatment

Mitigating Cancer-Related Cognitive Impairment in Older Adults With Breast Cancer Receiving Chemotherapy: Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase I Scientific Title

Purpose

To study if the MAAT-G intervention can improve or maintain cognition for older adults after completing breast cancer treatment.

Who is this for?

People ages 65 or older with stage I, stage II, or stage III breast cancer who have completed standard treatment with chemotherapy and have mild cognitive problems. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MAAT-G intervention, 8 workshops and workbook</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for cancer-related cognitive problems.</li> <li class="seamTextUnorderedListItem">MAAT is a series of workshops delivered by a psychologist via video-conferencing, supplemented by a workbook, which provides instruction and practice with behavioral coping skills, stress management techniques, and other support strategies. </li> <li class="seamTextUnorderedListItem">MAAT is used for younger cancer survivors, but needs to be adapted for older adults to address their unique needs. </li> <li class="seamTextUnorderedListItem">Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is MAAT for people over the age of 65.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04230941' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20100913' target='_blank'>Breastcancer.org: Older Women More Likely to Have Chemo-Related Cognitive Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/podcast/chemobrain-update' target='_blank'>Breastcancer.org (Podcast): Chemo Brain Update: Cancer-Related Cognitive Decline</a> </li></ul>

NEAREST SITE: 2352 miles
University of Rochester
Rochester,NY

VISITS: 5 visits over 3-5 months

PHASE: NA

NCT ID: NCT03137095

Memory Problems During Chemotherapy in Patients with Stage I-III Breast Cancer

Longitudinal Pilot Mechanistic Study of the Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants Scientific Title

Purpose

To see if and how your cognitive functioning skills, like memory and concentration, change as you receive chemotherapy.

Who is this for?

Women who have been recently diagnosed with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following over 3-5 months: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 computerized and paper-based cognitive tests during chemotherapy and 1 month after completion of chemotherapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will give you cognitive tests during your chemotherapy treatment and one month after you have completed treatment.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03137095' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: Number of visits unavailable, over 4 months

PHASE: II

NCT ID: NCT04249622

Rifaximin for Diarrhea in People Planning to Receive Pertuzumab for Stage I-III, HER2+ Breast Cancer

Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy Scientific Title

Purpose

To study if rifaximin lessens diarrhea and other gastrointestinal side effects in people receiving pertuzumab (Perjeta®).

Who is this for?

People with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer who will be receiving pertuzumab (Perjeta®) along with chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

If you experience diarrhea or other stomach-based side effects caused by receiving pertuzumab (Perjeta®), you will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rifaximin, by mouth, twice a day (or five days in a row), every 3 weeks, for 4 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®) is a HER2-targeted therapy used to treat HER2 positive (HER2+) breast cancer. One of its common side effects is diarrhea. </li> <li class="seamTextUnorderedListItem">Rifaximin is an antibiotic commonly used to treat traveler's diarrhea, but its use in this trial is considered experimental.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04249622' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/perjeta' target='_blank'>Breastcancer.org: Pertuzumab (Perjeta®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Rifaximin' target='_blank'>Wikipedia: Rifaximin</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic
Jacksonville,FL

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT04742231

Measuring Hand Strength During Brain Surgery to Predict How the Craniotomy Will Affect Motor Skills

Use of Handheld Dynamometer as a Novel Tool to Assess Motor Function During Awake Craniotomy for Brain Lesions Located Within or Adjacent to the Motor Cortex: A Single-Center Pilot Study Scientific Title

Purpose

To study the safety and reliability of measuring hand strength during an awake craniotomy to monitor how the surgery will affect your motor skills.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who will have an awake craniotomy at the Mayo Clinic in Jacksonville, Florida. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Your hand strength will be measured during surgery with a handheld device called a K-FORCE Grip dynamometer®.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A craniotomy is a type of brain surgery. The surgeon will remove part of your skull (cranium) to access your brain to remove the tumors. </li> <li class="seamTextUnorderedListItem">You will be awake during the craniotomy so that you can use a handheld device to monitor how the surgery is affecting your motor skills. </li> <li class="seamTextUnorderedListItem">Motor skills are body movements and include walking, hand movements (like writing), and other types of movement. </li> <li class="seamTextUnorderedListItem">K-FORCE Grip® is a handheld dynamometer. A dynamometer is a machine that is held in the hand and can measure the strength of your grip. </li> <li class="seamTextUnorderedListItem">Researchers believe measuring grip strength may predict how removing tumors will affect motor skills.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04742231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/craniotomy' target='_blank'>Johns Hopkins Medicine: Craniotomy?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/awake-brain-surgery/about/pac-20384913' target='_blank'>Mayo Clinic: Awake Brain Surgery</a> </li><li class='seamTextUnorderedListItem'><a href='https://k-invent.com/produit/k-force-grip/' target='_blank'>Kinvent Device Information Page: KForce Grip</a> </li></ul>

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: 2-4 visits

PHASE: NA

NCT ID: NCT01231932

Studying Fatigue in People with Stage I-IV Breast Cancer and Breast Cancer Survivors

Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors Scientific Title

Purpose

To understand how the immune system and body change during cancer treatment, how these changes cause fatigue, and how quality of life is affected by fatigue.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or people who have recently completed standard treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical exam</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Physical activity tracking with wearable device</li> <li class="seamTextUnorderedListItem">Journaling</li> <li class="seamTextUnorderedListItem">Cognitive games (optional)</li> <li class="seamTextUnorderedListItem">Strength test (optional)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fatigue is a common side effect of cancer and treatment. Previous research has shown that fatigue may be caused by a number of factors, including problems with the immune system response of the body while undergoing cancer treatment.</li> <li class="seamTextUnorderedListItem">A wearable device, such as a Fitbit, is device you wear that tracks your physical activity.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01231932' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/fatigue' target='_blank'>Breastcancer.org: Fatigue</a> </li></ul>

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Requires hospitalization

PHASE: NA

NCT ID: NCT02639325

Brain Surgery for Brain Metastasis and Tumor Related Epilepsy

Tumor Related Epilepsy Scientific Title

Purpose

To study if brain surgery reduces the number of seizures and to see how surgery affects seizures.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have no more than one brain tumor and have experienced at least one seizure associated with the tumor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Requires hospitalization for at least one week</li> <li class="seamTextUnorderedListItem">Questionnaires, cognitive assessments, and seizure diary</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. </li> <li class="seamTextUnorderedListItem">Researchers think surgery may improve outcomes for people with tumor-related epilepsy by stopping seizures or reducing the number of seizures.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02639325' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/brain-metastasis/' target='_blank'>MBCBrainMets.org: About Brain Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/treatments-brain-metastasis/#toggle-id-7' target='_blank'>MBCBrainMets.org: Brain Metastasis Treatments</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/brain-mets/' target='_blank'>Metastastic Trial Talk: Treating Breast Cancer Brain Mets</a> </li></ul>

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04054752

Immunotherapy to Boost the Immune System of People 60 or Older Who Have Finished Breast Cancer Treatment

A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy Scientific Title

Purpose

To see if the immunotherapy NT-I7 boosts the immune system enough for people who have finished treatment for breast cancer to have typical reactions to common vaccines.

Who is this for?

People, 60 or older, who have completed treatment for breast cancer within the last six months. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NT-I7</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NT-I7</li> <li class="seamTextUnorderedListItem">Vaccinations for a variety of illnesses, by injection, 4 times, over 6 months</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Treatments for breast cancer can weaken the immune system of older adults. </li> <li class="seamTextUnorderedListItem">A weakened immune system means that common vaccines do not work as well.</li> <li class="seamTextUnorderedListItem">NT-17 is an experimental immunotherapy. Researchers believe it will boost the immune system so that older adults who have finished treatment for breast cancer can have typical immune responses to vaccines.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people who have completed treatment for other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04054752' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html' target='_blank'>American Cancer Society: Why People with Cancer Are More Likely to Get Infections</a> </li><li class='seamTextUnorderedListItem'><a href='http://neoimmunetech.com/technology/page2020_ver3.html' target='_blank'>NeoImmuneTech Drug Information Page: NT-I7</a> </li></ul>

NEAREST SITE: 2433 miles
Sibley Memorial Hospital
Washington,DC

VISITS: Please contact the research site

PHASE: NA

NCT ID: NCT03223922

Preserving Cognitive Function With Whole Brain Radiation Therapy for Brain Metastases

Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study Scientific Title

Purpose

To evaluate how well genu-sparing whole brain radiation preserves cognitive function in patients with brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) that has not been treated with whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genu-sparing whole brain radiation therapy, once a day, 5 days a week</li> <li class="seamTextUnorderedListItem">Cognitive testing at baseline and at 4 , 6 and 12 months following completion of brain radiation</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genu-sparing whole brain radiation limits the radiation dose to a specific area in the brain (the genu of the corpus callosum).</li> <li class="seamTextUnorderedListItem">The genu (front part) of the corpus callosum is associated with cognitive and neuropsychiatric functioning.</li> <li class="seamTextUnorderedListItem">Researchers believe that reducing damage to this area may prevent the decline of cognitive and neuropsychiatric functioning.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03223922' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

NEAREST SITE: 2434 miles
Georgetown Lombardi Comprehensive Cancer Center
Washington,DC

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT05256745

Azeliragon to Decrease Cardiotoxicity and Cognitive Decline During Chemotherapy in Women with Stage I-III Breast Cancer

RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer Scientific Title

Purpose

To study the ability of azeliragon to decrease cardiotoxicity (heart damage caused by cancer treatment) and cognitive decline side effects of chemotherapy.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have not yet received treatment and are planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 4 groups: Group 1: Azeliragon with AC/T Chemotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®), 5.5 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 5.5 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), 5.5 months</li> </ul> Group 2: Azeliragon with CT Chemotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), 3-4 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 3-4 months</li> </ul> Group 3: Azeliragon with TCHP Chemotherapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), 4 months</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), 4 months</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), 4 months</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), 4 months</li> </ul> Group 4: Azeliragon with Combination of Chemotherapy and Targeted Therapy <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), 4 months</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), 3-4 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), 5.5 months</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), depending on type of cancer</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), 4 months, depending on type of cancer</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon is an experimental drug that may reduce cardiotoxicity and cognitive decline side effects of chemotherapy. It is also being studied for treating Alzheimer's and glioblastoma, a type of brain cancer.</li> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity. </li> <li class="seamTextUnorderedListItem">Doxorubicin (Adriamycin®), cyclophosphamide (Cytoxan®), paclitaxel (Taxol®), docetaxel (Taxotere®), and carboplatin (Paraplatin®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and Pertuzumab (Perjeta®) are anti-HER2 targeted therapies routinely used to treat HER2 positive breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05256745' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/16858-chemotherapy--the-heart-cardiotoxicity#:~:text=Cardiotoxicity%20refers%20to%20any%20heart,radiation%20therapy%20to%20the%20chest.' target='_blank'>Cleveland Clinic: Cardiotoxicity Cancer Treatment and the Heart</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-azeliragon-for-gbm' target='_blank'>OncLive: Azeliragon for Brain Cancer and Cancer Treatment-Related Complications</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>

NEAREST SITE: 2436 miles
MedStar Washington Hospital Center
Washington,DC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05233800

Faster Asleep Smart Speaker for Sleep Problems in Women with Breast Cancer

Testing mHealth Delivery of Cognitive Behavioral Therapy for Insomnia to Breast Cancer Survivors Scientific Title

Purpose

To study if the Faster Asleep Smart Speaker Program can reduce insomnia and help you sleep better.

Who is this for?

Women with stage I, stage II, stage III, or metastatic (stage IV) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Faster Asleep Smart Speaker Program, daily for 6 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Faster Asleep Website</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Faster Asleep Smart Speaker Program includes a speaker that can be activated by your voice or smartphone app. It automatically delivers components of cognitive behavioral therapy for insomnia (sleep problems).</li> <li class="seamTextUnorderedListItem">The Faster Asleep Website has information about cognitive behavioral therapy for insomnia (sleep problems) in people with breast cancer, including information from the Faster Asleep Smart Speaker Program script.</li> <li class="seamTextUnorderedListItem">Cognitive behavioral therapy helps connect the way we think, the things we do, and how we sleep.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05233800' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sleepfoundation.org/insomnia/treatment/cognitive-behavioral-therapy-insomnia' target='_blank'>Sleep Foundation: Cognitive Behavioral Therapy for Insomnia</a> </li></ul>

NEAREST SITE: 2437 miles
Penn State Cancer Institute
Hershey,PA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04478630

Aromatherapy to Prevent Nausea and Vomiting During Chemotherapy for Breast Cancer

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea and Vomiting (CINV) in Men and Women With Breast Cancer Scientific Title

Purpose

To study the ability of essential oils to prevent nausea and vomiting during chemotherapy.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving chemotherapy and have experienced chemotherapy-related nausea. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Peppermint or ginger essential oil, by inhalation, 8 days within 1-2 months</li> </ul> Group 2: Placebo <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pure vanilla extract, by inhalation, 8 days within 1-2 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatherapy is the use of scented essential oils that are inhaled through the nose or rubbed on the body.</li> <li class="seamTextUnorderedListItem">You will receive a pocket diffuser containing either ginger essential oil, peppermint essential oil, or vanilla extract.</li> <li class="seamTextUnorderedListItem">You will inhale the essential oil or vanilla extract daily for the first 4 days of 2 cycles of chemotherapy, which are typically 2-3 weeks apart.</li> <li class="seamTextUnorderedListItem">You will receive an educational handout as well as essential oil safety information.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04478630' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/complementary-therapy/types/aromatherapy' target='_blank'>Breastcancer.org: Aromatherapy</a> </li></ul>

NEAREST SITE: 2504 miles
Albert Einstein Medical Center Montgomery
East Norriton,PA

VISITS: 2 visits, over 3 months

PHASE: NA

NCT ID: NCT04554316

Steri Strips to Improve Cosmetic Outcomes and Reduce Infections from Biopsies, Lumpectomies and Mastectomies

Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery Scientific Title

Purpose

To study whether using Steri Strips on a surgical incision helps reduce infections and improves cosmetic outcomes.

Who is this for?

People receiving a biopsy, lumpectomy or mastectomy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Steri Strips placed over the surgical incision at the time of procedure</li> <li class="seamTextUnorderedListItem">Rating of scar appearance, at 1 month and 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Steri Strips are adhesive bandages sometimes used when people receive stitches.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04554316' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/health/steri-strips' target='_blank'>Healthline.com: Steri Strips</a> </li></ul>

NEAREST SITE: 2518 miles
Jefferson Health - Asplundh Cancer Pavilion
Willow Grove,PA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04054557

Telehealth and Smart Pill Bottles to Improve Adherence to Hormone Therapy for People with DCIS and Stage I-III Breast Cancer

Utilization of Telehealth to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients Scientific Title

Purpose

To study the ability of telehealth and smart pill bottles to improve adherence to hormone therapy, improve quality of life, and decrease side effects of hormone therapy.

Who is this for?

People with stage 0 (DCIS), stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have received hormone therapy for at least 4 years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In-person visits with oncologist, every 3 months for 1 year</li> </ul> Group 2: Standard of Care Plus Telehealth <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In-person visits with oncologist, every 3 months for 1 year</li> <li class="seamTextUnorderedListItem">Virtual visits with oncologist</li> <li class="seamTextUnorderedListItem">Electronic surveys, every 3 weeks for 1 year</li> </ul> Group 3: Smart Pill Bottle <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Smart pill bottle, 1 year</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Adherence to hormone therapy is when you take your hormone therapy as prescribed by your doctor.</li> <li class="seamTextUnorderedListItem">Telehealth is virtual visits with your doctor by video chat on a computer or smart phone.</li> <li class="seamTextUnorderedListItem">Telehealth may improve the ability of your doctor to identify side effects of hormone therapy.</li> <li class="seamTextUnorderedListItem">The smart pill bottle gives daily reminders to open the pill bottle and take your medication. Additional messages are triggered by the pill bottle when non-adherence is indicated, such as when the bottle is not opened or the number of pills does not change.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04054557' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>

NEAREST SITE: 2521 miles
Fox Chase Cancer Center
Philadelphia,PA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05636943

Improving Sexual and Emotional Intimacy for Women with Metastatic Breast Cancer

Quality of Life for Couples Facing Metastatic Breast Cancer Scientific Title

Purpose

To study whether intimacy enhancement sessions improve sexual and emotional intimacy for women with metastatic breast cancer and their romantic partners.

Who is this for?

Women with stage IV (metastatic) breast cancer who live with a romantic partner (same or opposite sex) for at least 6 months and have sexual intimacy concerns. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You and your romantic partner will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive intimacy enhancement sessions with partner, 4 virtual sessions</li> <li class="seamTextUnorderedListItem">Read a booklet with partner about intimacy and metastatic breast cancer</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Read a booklet with partner about intimacy and metastatic breast cancer</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 surveys over 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intimacy enhancement sessions are virtual 60-75 minute sessions with a couples coach consisting of education and skills to enhance physical and emotional intimacy.</li> <li class="seamTextUnorderedListItem">The booklet contains self-guided readings and resources about intimacy and metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">This trial requires participation from you and your partner.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05636943' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/metastatic/sexuality' target='_blank'>Breastcancer.org: Sexuality and Metastatic Breast Cancer</a> </li></ul>

NEAREST SITE: 2531 miles
Virtua Health
Voorhees,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05704842

Exercise to Reduce Fatigue During Chemotherapy for Women with Stage I-III Breast Cancer

Pilot Study to Evaluate the Impact of a Home-Based Exercise Program on Cancer-Related Fatigue in Breast Cancer Patients Undergoing Curative-Intent Chemotherapy Scientific Title

Purpose

To study if exercise reduces fatigue during treatment with chemotherapy.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who plan to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visit with physical therapist</li> <li class="seamTextUnorderedListItem">Complete home-based exercise program</li> <li class="seamTextUnorderedListItem">Complete online surveys, weekly</li> </ul> Group 2: Standard Treatment <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete online surveys, weekly</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The home-based exercise program includes exercises such as: core stabilization, core extension, leg extensions, squats with and without weights, shoulder exercises, and arm exercises.</li> <li class="seamTextUnorderedListItem">The online surveys will assess your symptoms and fatigue.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05704842' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/fatigue' target='_blank'>Breastcancer.org: Cancer Fatigue</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (Consent and Followup)
Basking Ridge,NJ

VISITS: Coincides with surgery

PHASE: III

NCT ID: NCT04241341

Axillary Lymph Node Dissection with or without Immediate Lymph Reconstruction to Prevent Lymphedema

A Randomized Controlled Trial: Does Immediate Lymphatic Reconstruction Decrease the Incidence of Lymphedema After Axillary Lymph Node Dissection Scientific Title

Purpose

To study whether having immediate lymphatic reconstruction (ILR) during an axillary lymph node dissection (removal of lymph nodes from the underarm area) reduces a woman's risk of developing lymphedema.

Who is this for?

Women planning to have an axillary lymph node dissection. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary lymph node dissection (ALND)</li> <li class="seamTextUnorderedListItem">Lymphatic reconstruction immediately following your ALND</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axillary lymph node dissection (ALND)</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Quality of life questionnaires</li> <li class="seamTextUnorderedListItem">Standard lymphedema measurements, every 6 months for 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a painful swelling of the hand, wrist, or arm that can occur after breast cancer surgery. </li> <li class="seamTextUnorderedListItem">Axillary lymph node dissection (ALND) is a surgical procedure done to see if the cancer has spread to the lymph nodes located in your armpit (axilla). It can increase your risk for lymphedema. </li> <li class="seamTextUnorderedListItem">Immediate lymphatic reconstruction is a procedure that will be performed immediately after your ALND and is designed to improve lymphatic drainage.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04241341' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-cancer/lymph-node-surgery-for-breast-cancer.html' target='_blank'>American Cancer Society: Lymph Node Surgery for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/oncolog/advances-in-surgical-management-of-lymphedema.h13-1591413.html' target='_blank'>MD Anderson Cancer Center: Advances in Surgical Management of Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/lymphedema-what-are-your-surgical-options' target='_blank'>Johns Hopkins Medicine: Lymphedema, What Are Your Surgical Options?</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (Consent and follow-up only)
Basking Ridge,NJ

VISITS: Coincides with surgery

PHASE: III

NCT ID: NCT03351348

Bupivacaine to Reduce Pain After Mastectomy for DCIS and Stage I-III Breast Cancer

Double Blind, Randomized, Placebo Controlled Trial of Locally Instilled Bupivacaine in the Surgical Bed After Unilateral Mastectomy Without Reconstruction Scientific Title

Purpose

To study the ability of bupivacaine with standard of care pain medications to reduce pain after a mastectomy.

Who is this for?

Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer planning to receive a unilateral mastectomy without immediate reconstruction at Memorial Sloan Kettering Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for bupivacaine, by surgical drain</li> <li class="seamTextUnorderedListItem">Standard of care pain medications</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine, by surgical drain</li> <li class="seamTextUnorderedListItem">Standard of care pain medications</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, 2 times within 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine is a FDA-approved numbing medicine used for some surgical and dental procedures.</li> <li class="seamTextUnorderedListItem">The addition of bupivacaine to the surgical wound site with standard of care pain medications could better manage your pain immediately after surgery and reduce the amount of opioid medications taken after surgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03351348' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/bupivacaine-injection-route/description/drg-20406723#:~:text=Bupivacaine%20injection%20is%20used%20to,It%20is%20a%20local%20anesthetic.' target='_blank'>Mayo Clinic: Bupivacaine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mastectomy/expert-answers/pain-after-breast-surgery/faq-20058049' target='_blank'>Mayo Clinic: Pain After Breast Surgery</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: 5 visits

PHASE: NA

NCT ID: NCT05590949

Studying Bone Changes in Post-Menopausal Women with Stage I-IV Breast Cancer After Treatment with Aromatase Inhibitor and Denosumab

Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation Scientific Title

Purpose

To gather information about changes in the bones after stopping treatment with an aromatase inhibitor and denosumab (Xgeva®).

Who is this for?

Postmenopausal women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have completed treatment with an aromatase Inhibitor before or within 6 months of completing at least 2 doses of denosumab (Xgeva®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical exam, 5 visits within 2 years</li> <li class="seamTextUnorderedListItem">DEXA scan, 2 times within 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The physical exam will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work.</li> <li class="seamTextUnorderedListItem">Dual-energy X-ray absorptiometry (DEXA) scans use x-ray energy to measure bone density (thickness and strength of bones).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05590949' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/nceh/radiation/dexa-scan.html#:~:text=DEXA%20(dual%20x%2Dray%20absorptiometry,the%20hip%20and%20the%20spine.' target='_blank'>CDC: DEXA Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a610023.html' target='_blank'>MedlinePlus: Denosumab (Xgeva®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: At least 1 visit per month

PHASE: II

NCT ID: NCT05090358

Preventing High Blood Sugar in People with Metastatic ER+, HER2- Breast Cancer with a PIK3CA Mutation

Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer Scientific Title

Purpose

To determine if a ketogenic or low carbohydrate diet with canagliflozin (Invokana®), a high blood pressure drug, or canagliflozin (Invokana®) alone can prevent high blood sugar.

Who is this for?

Post-menopausal women and men with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation who have not received chemotherapy or more than 1 line of hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ketogenic diet</li> <li class="seamTextUnorderedListItem">Canagliflozin (Invokana®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Low carbohydrate diet</li> <li class="seamTextUnorderedListItem">Canagliflozin (Invokana®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Canagliflozin (Invokana®), by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), injection, every 2 weeks for 1 month, then monthly</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The ketogenic diet consists of low carbohydrates and high fat.</li> <li class="seamTextUnorderedListItem">Canagliflozin (Invokana®) is a drug approved for treating high blood sugar for people with type 2 diabetes. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">SERDs work by binding to and breaking down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor.</li> <li class="seamTextUnorderedListItem">If there is a mutation in the PIK3CA gene, the PI3K pathway can become overactivated, which allows cancer cells to grow. PI3K inhibitors block the PI3K pathway.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05090358' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://osher.ucsf.edu/patient-care/integrative-medicine-resources/cancer-and-nutrition/faq/low-carbohydrate-diet' target='_blank'>UCSF Osher Center for Integrative Health: Low Carbohydrate Diet and Ketogenic Diet</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/nutrition/low-carb-vs-keto' target='_blank'>Healthline: Low Carbohydrate Diet and Ketogenic Diet</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.invokana.com/' target='_blank'>Janssen Drug Information Page: Canagliflozin (Invokana®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li></ul>

NEAREST SITE: 2541 miles
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton,NJ

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05559164

Reducing Treatment-Related Heart Problems From Anti-HER2 Targeted Therapy

STACIE: Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy Scientific Title

Purpose

To study whether atorvastatin (Lipitor®) reduces treatment delays or early discontinuations of anti-HER2 targeted therapy due to treatment-related heart problems.

Who is this for?

Women with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer who are planning to receive treatment with anti-HER2 targeted therapy. You must not currently be receiving any cholesterol drugs. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atorvastatin (Lipitor®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 1.25 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments including anti-HER2 targeted therapy can cause or increase the risk of heart problems, which is called cardiotoxicity. </li> <li class="seamTextUnorderedListItem">Atorvastatin (Lipitor®) is a cholesterol drug called a statin. Statins lower <q>bad cholesterol</q> which may reduce the risk of heart problems.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05559164' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statins/art-20045772' target='_blank'>Mayo Clinic: Statins Including Atorvastatin (Lipitor®)</a> </li></ul>

NEAREST SITE: 2561 miles
Memorial Sloan Kettering Bergen
Montvale,NJ

VISITS: 8 to 10 times for 2-3 years, then once a year for 2-3 years

PHASE: NA

NCT ID: NCT00823654

Measuring Hormone Levels to Study How Cancer Treatments & Inherited BRCA 1/2 Mutations Affect The Ovaries

Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer and Lymphoma Scientific Title

Purpose

To study if a blood test that measures hormones can predict who will enter early menopause or develop fertility issues because of how chemotherapy and hormone therapy affect the ovaries; and to study the fertility and sexual health of women with inherited BRCA 1 or BRCA 2 mutations.

Who is this for?

Premenopausal women, 44 or younger, with DCIS or stage I, stage II, or stage III breast cancer planning to receive chemotherapy or tamoxifen. You may also enroll if you do not have breast cancer but have an inherited BRCA 1 or BRCA 2 mutation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Women with DCIS or stage I-III breast cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws, 8-10 times for 2-3 years, then once a year for 2-3 years (5 years total)</li> </ul> Group 2: Women with inherited BRCA mutations <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws, 5 times for the first year, then optional draws once a year for 4 years (5 years total)</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer treatments can affect the ovaries, which may cause early menopause or difficulty becoming pregnant. </li> <li class="seamTextUnorderedListItem">Ovarian functioning can be assessed by evaluating the blood levels of certain hormones the ovaries produce.</li> <li class="seamTextUnorderedListItem">Inherited BRCA 1/2 mutations may affect your ovaries.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00823654' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youngsurvival.org' target='_blank'>Young Survival Coalition</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.facingourrisk.org/index.php' target='_blank'>FORCE: Facing Our Risk of Cancer Empowered</a> </li></ul>

NEAREST SITE: 2566 miles
University of Vermont College of Medicine
Burlington,VT

VISITS: 5 visits per week for 2 months

PHASE: I-II

NCT ID: NCT02739620

Exercise Program to Improve Skeletal Muscle Function and Fatigue After Chemotherapy

Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors Scientific Title

Purpose

To see if a rehabilitation program that uses electrical stimulation to make muscles contract offers the same benefits as exercise.

Who is this for?

Women who have received or are currently receiving chemotherapy to treat breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuromuscular electrical stimulation, 5 times/week for one hour, for 2 months.</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Exercise can be beneficial for breast cancer survivors. </li> <li class="seamTextUnorderedListItem">However, cost, lack of transportation and other problems may make it hard for some survivors to exercise. </li> <li class="seamTextUnorderedListItem">The type of rehabilitation used is called neuromuscular electrical stimulation. It is currently used to treat patients recovering from certain types of injuries, surgeries or diseases.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02739620' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2566 miles
Englewood Health
Englewood,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04116697

Acupuncture and Aromatherapy for Chemotherapy Side Effects for People with Breast Cancer

A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan Scientific Title

Purpose

To study the ability of acupuncture or aromatherapy with anti-nausea medication to lessen nausea, vomiting, and anxiety side effects of chemotherapy.

Who is this for?

Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive treatment with doxorubicin (Adriamycin®) or cyclophosphamide (Cytoxan®) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acupuncture</li> <li class="seamTextUnorderedListItem">Anti-nausea medication</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatherapy</li> <li class="seamTextUnorderedListItem">Anti-nausea medication</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Anti-nausea medication</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.</li> <li class="seamTextUnorderedListItem">Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.</li> <li class="seamTextUnorderedListItem">Anti-nausea medication is standard of care.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04116697' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/complementary-therapy/types/acupuncture' target='_blank'>Breastcancer.org: Acupuncture</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/complementary-therapy/types/aromatherapy' target='_blank'>Breastcancer.org: Aromatherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/resources-support/complementary-integrative-medicine/' target='_blank'>Metastatictrialtalk.org: What is Complementary and Integrative Medicine?</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center
New York,NY

VISITS: 1 visit including surgery, may require hospitalization

PHASE: III-IV

NCT ID: NCT04016376

Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction

Cluster-Randomized, Prospective Assessment of Postoperative Pain Management in Patients Undergoing Bilateral Mastectomy With Immediate Reconstruction With Tissue Expander (BMWRw/TE) Using Preoperative Paravertebral (PVB), Serratus+PECS-1, or PVB+PECS-1 Nerve Blocks Scientific Title

Purpose

To study whether nerve blocks before surgery reduce the need for pain medication after surgery.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive a bilateral mastectomy with immediate reconstruction at the Memorial Sloan Kettering Josie Robertson Surgical Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PVB nerve block, by injection in back</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PVB nerve block, by injection in back</li> <li class="seamTextUnorderedListItem">PECS-1 nerve block, by injection in chest</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PECS-1 nerve block, by injection in chest</li> <li class="seamTextUnorderedListItem">Serratus nerve block, by injection in chest</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nerve blocks are a type of local anesthesia given before surgery.</li> <li class="seamTextUnorderedListItem">Anesthesia is medication that prevents pain during surgery.</li> <li class="seamTextUnorderedListItem">PVB, PECS-1, and/or serratus nerve blocks may also reduce the need for pain medication after surgery.</li> <li class="seamTextUnorderedListItem">You will receive an injection of anesthesia into a different part of your body for each nerve block.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04016376' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/conditions-and-diseases/nerve-blocks#:~:text=Nerve%20blocks%2C%20or%20neural%20blockades,feeling%20if%20needed%20for%20surgery.' target='_blank'>Johns Hopkins Medicine: Nerve Blocks</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.yalemedicine.org/conditions/nerve-blocks-for-surgery' target='_blank'>Yale Medicine: Nerve Blocks For Surgery</a> </li></ul>

NEAREST SITE: 2569 miles
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center
New York,NY

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT04973930

Tele-Interpersonal Psychotherapy or Medication for People with Depression and Breast Cancer

Pilot Randomized Feasibility Trial of Tele-Interpersonal Psychotherapy and Tele-Pharmacotherapy for Depression in Patients With Non-Metastatic Breast Cancer Scientific Title

Purpose

To study if tele-interpersonal psychotherapy (IPT) and/or medication decreases symptoms of depression.

Who is this for?

People with stage I, stage II, or stage III breast cancer and depression. You must not be currently receiving treatment for depression. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tele-interpersonal psychotherapy (IPT), by Zoom, once a week, for 3 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Venlafaxine (Effexor®) or escitalopram (Lexapro®), by mouth, daily for 3 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Requires blood tests and questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interpersonal psychotherapy (IPT) is a type of therapy that focuses on the connection between upsetting life circumstances (such as diagnosis of breast cancer) and their effect on mood. It is known to lower symptoms of depression.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, you will receive tele-IPT virtually through Zoom videoconferencing software. </li> <li class="seamTextUnorderedListItem">Venlafaxine (Effexor®) and escitalopram (Lexapro®) are two types of approved anti-depression treatments called serotonin reuptake inhibitors.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, you will meet with a doctor virtually to discuss your treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04973930' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/depression' target='_blank'>Breastcancer.org: Depression and Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.psychologytoday.com/us/therapy-types/interpersonal-psychotherapy' target='_blank'>Psychology Today: Interpersonal Psychotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Venlafaxine-(Effexor)' target='_blank'>National Alliance on Mental Illness: Venlafaxine (Effexor®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Escitalopram-(Lexapro)' target='_blank'>National Alliance on Mental Illness: Escitalopram (Lexapro®)</a> </li></ul>

NEAREST SITE: 2573 miles
Cleveland Clinic Florida
Weston,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05598879

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Global Cardio Oncology Registry Scientific Title

Purpose

To collect information on the diagnosis and treatment of cardiovascular health and risk factors in people with breast cancer.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of health information</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">This study uses clinical, laboratory, imaging, demographic, and socioeconomic information to study cardiovascular (heart and blood vessels) health and risk factors before, during, or after cancer treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05598879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.heart.org/en/news/2020/02/19/what-women-need-to-know-about-breast-cancer-and-heart-disease' target='_blank'>American Heart Association: Breast Cancer and Heart Disease</a> </li></ul>

NEAREST SITE: 2583 miles
Holy Cross Hospital
Fort Lauderdale,FL

VISITS: Coincides with surgery

PHASE: III

NCT ID: NCT03927027

Preventing Lymphedema in Women Having Breast Surgery and a Lymph Node Dissection

ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping Scientific Title

Purpose

To see if using a surgical technique called Axillary Reverse Mapping during surgery to remove lymph nodes from your underarm area (axillary lymph node dissection) prevents lymphedema.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have not yet had surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Isosulfan Blue, by injection, during surgery</li> <li class="seamTextUnorderedListItem">Axillary Lymph Node Dissection (ALND)</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Isosulfan Blue, by injection, during surgery</li> <li class="seamTextUnorderedListItem">Axillary Lymph Node Dissection (ALND)</li> <li class="seamTextUnorderedListItem">Axillary Reverse Mapping (ARM), during ALND</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is abnormal swelling in the arm, hand, breast, or torso that may develop as a side effect of some breast cancer surgeries. </li> <li class="seamTextUnorderedListItem">Lymphedema happens when there is a blockage in your lymphatic system (a part of your immune system) that stops the lymph fluid from draining well. The fluid buildup causes the abnormal swelling. </li> <li class="seamTextUnorderedListItem">The surgery that removes lymph nodes from your underarm area is called an axillary lymph node dissection (ALND). This surgery may cause a blockage in your lymphatic system.</li> <li class="seamTextUnorderedListItem">During your ALND, a blue dye will be used to see your lymph nodes and the lymphatic channels that drain your arm. </li> <li class="seamTextUnorderedListItem">Axillary Reverse Mapping (ARM) is when your surgeon tries to avoid disrupting the lymph nodes and lymphatic channels that drain your arm. This may prevent you from developing lymphedema.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03927027' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/diseases-conditions/lymphedema/symptoms-causes/syc-20374682' target='_blank'>Mayo Clinic: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-pdq' target='_blank'>NCI: Lymphedema (PDQ®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/uploadedFiles/_Komen/Content/About_Breast_Cancer/Tools_and_Resources/Fact_Sheets_and_Breast_Self_Awareness_Cards/AxillaryLymphNodes.pdf' target='_blank'>Susan G. Komen: Axillary Lymph Nodes</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ons.org/node/1531?display=pepnavigator&sort_by=created&items_per_page=50' target='_blank'>Oncology Nursing Society: Axillary Reverse Mapping (ARM)</a> </li><li class='seamTextUnorderedListItem'><a href='https://breast360.org/topic/2017/01/01/axillary-reverse-mapping/' target='_blank'>Breast360.org: Axillary Reverse Mapping</a> </li></ul>

NEAREST SITE: 2691 miles
Massachusetts General Hospital
Boston,MA

VISITS: Coincides with standard follow-up care

PHASE: NA

NCT ID: NCT01521741

Impact of Lymphedema on Quality of Life After Breast Cancer

Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer. Scientific Title

Purpose

To determine how the symptoms and functional disability that accompany lymphedema can impact breast cancer survivors' quality of life.

Who is this for?

Women with breast cancer without axillary lymph node malignancy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires and arm measurements</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer treatments can result in long-term, painful swelling of the arm and hand, a condition called lymphedema.</li> <li class="seamTextUnorderedListItem">To be eligible, participants must be planning to have surgery and receive follow-up care for breast cancer at Massachusetts General Hospital.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01521741' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/lymphedema' target='_blank'>BreastCancer.org: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-pdq#section/all' target='_blank'>National Cancer Institute: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/lymphedema.html' target='_blank'>American Cancer Society: Lymphedema</a> </li></ul>

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: 1-2 visits per week for 3 months

PHASE: NA

NCT ID: NCT05528263

Acupuncture to Prevent Chemotherapy-Induced Peripheral Neuropathy for People with Stage I-III Breast Cancer

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture, A Randomized Controlled Trial (PACT Trial) Scientific Title

Purpose

To study the ability of acupuncture to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Who is this for?

People with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acupuncture, 1-2 times per week for 3 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nature scenery video with relaxation exercise guide, 1-2 times per week for 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy-induced peripheral neuropathy (CIPN) is nerve pain in your hands and feet as a side effect of chemotherapy.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Acupuncture is a form of complementary medicine in which thin needles are inserted into the body.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05528263' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/complementary-therapy/types/acupuncture#:~:text=Research%20on%20acupuncture%20in%20people%20with%20breast%20cancer%20and%20other%20types%20of%20cancer,-Advertisement&text=Much%20research%20is%20being%20done,nausea%2C' target='_blank'>Breastcancer.org: Acupuncture</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li></ul>

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: 1 visit every 1-3 weeks

PHASE: II

NCT ID: NCT04986579

Scalp Cooling to Prevent Hair Loss During Chemotherapy for People With Metastatic Breast Cancer

Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer Scientific Title

Purpose

To study the ability of the Paxman Scalp Cooling System to prevent hair loss during treatment with chemotherapy.

Who is this for?

People with metastatic (stage IV) breast cancer that are planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Chemotherapy with Scalp Cooling <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paxman Scalp Cooling System, every 3 weeks</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), sacituzumab govitecan (Trodelvy®), or trastuzumab deruxtecan (Enhertu®), by IV, every 1-3 weeks</li> </ul> Group 2: Chemotherapy without Scalp Cooling <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), sacituzumab govitecan (Trodelvy®), or trastuzumab deruxtecan (Enhertu®), by IV, every 1-3 weeks</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Paxman Scalp Cooling System is FDA-approved for preventing hair loss for people undergoing chemotherapy.</li> <li class="seamTextUnorderedListItem">The Paxman Scalp Cooling System has not been studied to look at its ability to prevent hair loss in patients specifically receiving eribulin (Halaven®), sacituzumab govitecan (Trodelvy®), or trastuzumab deruxtecan (Enhertu®).</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a HER2-targeted antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a Trop-2-targeted antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04986579' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://coldcap.com//?lang=us' target='_blank'>Paxman: Paxman Scalp Cooling System</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/managing-hair-loss-scalp-cooling' target='_blank'>Memorial Sloan Kettering Cancer Center: Scalp Cooling</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/halaven' target='_blank'>Breastcancer.org: Eribulin (Halaven®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/trodelvy' target='_blank'>Breastcancer.org: Sacituzumab govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab deruxtecan (Enhertu®)</a> </li></ul>

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: 4 visits over 8 months

PHASE: NA

NCT ID: NCT05327452

Exercise During Chemotherapy for Black and Hispanic People with Breast Cancer

Testing Home-based Exercise Strategies to Improve Exercise Participation and Cardiovascular Health in Underserved Minority Patients With Cancer Undergoing Chemotherapy: the THRIVE Study Scientific Title

Purpose

To determine whether an exercise intervention will affect physical activity levels and heart health in Black and Hispanic people with breast cancer.

Who is this for?

Black and Hispanic people newly diagnosed with stage I, stage II, or stage III breast cancer who are overweight/obese, engage in less than 90 minutes of exercise per week, and are planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtually supervised home-based exercise, 3 times per week for 4 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Unsupervised home-based exercise, 3 times per week for 4 months</li> <li class="seamTextUnorderedListItem">Telehealth call with certified exercise trainer, 1 time per week for 4 months</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Home-based stretching, 3 times per week for 4 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardiovascular and strength tests, 3 times within 8 months</li> <li class="seamTextUnorderedListItem">Questionnaires, 3 times within 8 months</li> </ul> All groups require 4 visits
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The home-based exercise interventions include aerobic and resistance exercises.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, the virtual supervision will occur via Zoom.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05327452' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/exercise' target='_blank'>Breastcancer.org: Exercise</a> </li></ul>

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04379414

YES Portal for Monitoring Symptoms and Providing Support for Women Ages 18-39 with Breast Cancer

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Newly Diagnosed/Metastatic Intervention Scientific Title

Purpose

To study the ability of the web-based YES portal to monitor cancer symptoms and provide support and educational resources.

Who is this for?

Women newly diagnosed with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer between the ages of 18-39 years who are planning to receive treatment at Dana-Farber Cancer Institute. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Access to YES portal, weekly for 3 months, then monthly</li> <li class="seamTextUnorderedListItem">Surveys, every 6 months for 3 years, then yearly for 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Young, Empowered, and Strong (YES) portal is a web-based portal designed to help monitor cancer-related issues and to share self-management information, resources, and potential research opportunities.</li> <li class="seamTextUnorderedListItem">The portal is also designed to create a community among participants through the yeschat.org discussion board.</li> <li class="seamTextUnorderedListItem">The portal can be accessed by smartphone, tablet, or laptop/desktop.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04379414' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/clinical-trials2/detail/20-124/' target='_blank'>Dana-Farber Cancer Institute Trial Information Page: YES Portal</a> </li><li class='seamTextUnorderedListItem'><a href='https://youngandstrong.dana-farber.org/' target='_blank'>Dana-Farber Cancer Institute: Young and Strong</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/CCI.21.00067' target='_blank'>Abstract: YES Portal</a> </li></ul>

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: 1 visit

PHASE: II

NCT ID: NCT04482244

CBD for Anxiety for People with Metastatic Breast Cancer

Randomized, Double-blind Phase II Study of a Single Dose of Cannabidiol (CBD) for Acute Anticipatory Anxiety in Advanced Breast Cancer Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-anxiety activity of an FDA-approved cannabidiol (CBD), Epidiolex®.

Who is this for?

Women with metastatic (stage IV) breast cancer that experience anxiety before scans. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cannabidiol (Epidiolex®), by mouth, 1 dose before scan</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for cannabidiol (Epidiolex®), by mouth, 1 dose before scan</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cannabidiol (CBD) is a component of the cannabis sativa (marijuana) plant and of hemp.</li> <li class="seamTextUnorderedListItem">Studies of CBD have led to its approval by the FDA for certain childhood seizure disorders. Researchers have also been studying the use of CBD to manage anxiety and pain.</li> <li class="seamTextUnorderedListItem">Cannabidiol (Epidiolex®) is an FDA-approved seizure drug.</li> <li class="seamTextUnorderedListItem">You will receive either cannabidiol (Epidiolex®) or the placebo before a CT scan or PET scan.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04482244' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938286/' target='_blank'>National Institutes of Health: Cannabidiol (Epidiolex®) Frequently Asked Questions for Patients and Caregivers</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/special-topics/mbc-and-cannabis/' target='_blank'>Metastatic Trial Talk: Cannabis Use For Managing Symptoms and Side Effects</a> </li></ul>

NEAREST SITE: 2694 miles
BU School of Medicine
Boston,MA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05595213

Wrist Cooling for Hot Flashes for Women with Breast Cancer

Double Blind Randomized Pilot Evaluation of the Response Profiles of Wrist Cooling Devices for Men With Prostate Cancer and Women With Breast Cancer on Hormone Deprivation Therapy Who Suffer From Moderate and or Severe Hot Flashes Scientific Title

Purpose

To study if a wrist cooling device helps reduce the severity of hot flashes for women with breast cancer.

Who is this for?

Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving hormone therapy and experience at least 2 hot flashes per day. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear wrist cooling device, 1.5 months</li> <li class="seamTextUnorderedListItem">Complete hot flash diary, 1.5 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The wrist cooling device is worn like a watch. Pressing the button activates the cooling function to begin to cool the wrist skin temperature.</li> <li class="seamTextUnorderedListItem">You will receive a wrist cooling device that cools up to 5 minutes or up to 5 seconds.</li> <li class="seamTextUnorderedListItem">In the hot flash diary, you will be asked to document each hot flash experience and if you used the wrist cooling device.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05595213' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/ency/patientinstructions/000826.htm' target='_blank'>MedlinePlus: Cancer Treatment and Hot Flashes</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05612100

Studying Alopecia During Hormone Therapy in Women with Breast Cancer

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors Scientific Title

Purpose

To study the incidence, timing, duration, and severity of alopecia (hair loss) during hormone therapy.

Who is this for?

Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 2 years</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">While alopecia (hair loss) is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing hormone therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05612100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss' target='_blank'>Breastcancer.org: Alopecia/Hair Loss</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05692960

Improving Sexual Health for Women After Breast Cancer Treatment

Women's Interventions for Sexual Health: WISH, A Pilot Study Scientific Title

Purpose

To study the ability of hypnotic relaxation intervention (HRI) and Replens™ vaginal moisturizer to improve the sexual health of women after breast cancer treatment by addressing changes in body image, sexual desire, and vaginal dryness.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have completed treatment between 3 months and 5 years ago. You must experience dryness and/or pain with sexual activity and negative changes in your body image and/or sexual desire since being diagnosed with cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypnotic relaxation intervention (HRI) via MP3 player, 3 times per week for 1.5 months</li> <li class="seamTextUnorderedListItem">Hypnotic relaxation intervention (HRI) practice log, weekly for 1.5 months</li> <li class="seamTextUnorderedListItem">Replens™ vaginal moisturizer, every 1-2 days for 2 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Replens™ vaginal moisturizer, every 1-2 days for 2 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Phone calls and virtual visits, 4-5 times within 2 months</li> <li class="seamTextUnorderedListItem">Surveys, 3 times within 2 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The hypnotic relaxation intervention (HRI) consists of three different audio files, each about 20 minutes in length, from a trial-provided MP3 player. These three hypnotic inductions involve relaxation and subconscious suggestions that build upon each other.</li> <li class="seamTextUnorderedListItem">The first hypnotic induction audio focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second hypnotic induction audio focuses more specifically on body image related to sexuality and being a sexual being. The third hypnotic induction audio focuses on sexual desire, passion, and energy.</li> <li class="seamTextUnorderedListItem">Vulvovaginal dryness will be treated with a daily moisturizer for two weeks, then every other day for the remaining six weeks. Replens™ vaginal moisturizer will be applied at night, before sleep and after all sexual activity.</li> <li class="seamTextUnorderedListItem">Replens™ is a non-hormonal vaginal moisturizer consisting primarily of purified water, glycerin, and mineral oil.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05692960' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/sex-intimacy' target='_blank'>Breastcancer.org: Sexual Health During and After Breast Cancer</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: III

NCT ID: NCT05703178

Web-Based Coping Skills Training to Decrease Pain from Hormone Therapy

Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence Caused by Aromatase Inhibitor-Associated Arthralgia In Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial Scientific Title

Purpose

To study if an online pain coping skills training program reduces the severity and effects of pain from treatment with aromatase inhibitors.

Who is this for?

Postmenopausal women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have completed treatment. You must be taking an aromatase inhibitor and experience pain in your joints, bones, and/or muscles. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online pain coping skills training program, weekly for 2-3 months</li> <li class="seamTextUnorderedListItem">Educational booklet about aromatase inhibitors and side effects</li> <li class="seamTextUnorderedListItem">Electronic pill bottle to track use of aromatase inhibitor medication</li> <li class="seamTextUnorderedListItem">Continue usual care</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational booklet about aromatase inhibitors and side effects</li> <li class="seamTextUnorderedListItem">Electronic pill bottle to track use of aromatase inhibitor medication</li> <li class="seamTextUnorderedListItem">Continue usual care</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 9-10 months</li> <li class="seamTextUnorderedListItem">Virtual visits, 3 times within 1 month</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy that block some production of estrogen that helps cancer grow. Approved aromatase inhibitors include anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Arthralgia is pain in the joints, bones, and/or muscles and is a common side effect of aromatase inhibitors.</li> <li class="seamTextUnorderedListItem">The online pain coping skills training is an interactive, web-based program that teaches cognitive and behavioral skills to reduce pain and pain-related interference with daily activities. The program includes 8 sessions that are 35-45 minutes each. You will complete about 1 session per week.</li> <li class="seamTextUnorderedListItem">If you do not have a device capable of accessing the program, you will be loaned a tablet computer for the study.</li> <li class="seamTextUnorderedListItem">Benefits of the online pain coping skills training may include reduced severity of pain, improvements in quality of life, and improved adherence to aromatase inhibitor medication. The training may also increase your confidence in managing your pain and reduce unhelpful thinking patterns about pain.</li> <li class="seamTextUnorderedListItem">The educational booklet contains information about aromatase inhibitors, side effects including arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other side effects.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05703178' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.scholars.northwestern.edu/en/projects/web-based-pain-coping-skills-training-to-improve-pain-and-poor-ad' target='_blank'>Northwestern University: Pain Coping Skills Training</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/hormone-therapy/aromatase-inhibitors/side-effects/' target='_blank'>Susan G Komen: Side Effects of Aromatase Inhibitors</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05452681

Improving Quality of Life of Young Black Women After Treatment

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors Scientific Title

Purpose

To compare how Y-AMBIENT education sessions and follow up phone calls improve quality of life after breast cancer treatment.

Who is this for?

Black or African American women ages 18 to 44 years old with stage I, stage II, or stage III breast cancer who have completed treatment with chemotherapy and/or radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Y-AMBIENT education sessions, 3 times within 4 months</li> <li class="seamTextUnorderedListItem">Y-AMBIENT follow up phone calls, 3 times within 4 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Education sessions, 3 times within 4 months</li> <li class="seamTextUnorderedListItem">Follow up phone calls, 3 times within 4 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Y-AMBIENT is telephone-based intervention with education sessions designed to improve quality of life. Session 1, titled <q>My Self, My Soul,</q> covers topics related to spiritual growth and finding meaning in illness. Session 2, titled <q>My Body,</q> covers topics related to breast changes, aches/pains, fatigue, and weight changes. Session 3, titled <q>My Mind and My Relationships,</q> covers topics related to anxiety, fear, and relationships with others.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, education sessions include a culturally-targeted cookbook and a guide to grocery shopping smart.</li> <li class="seamTextUnorderedListItem">For both groups, all sessions will take approximately one hour, and follow-up phone calls will last about 20 minutes.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05452681' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/survivorship/health-concerns/quality-of-life/#:~:text=Quality%20of%20life%20after%20treatment,even%20years%20after%20treatment%20ends.' target='_blank'>Susan G. Komen: Quality of Life After Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/pcd/issues/2016/16_0096.htm' target='_blank'>Centers for Disease Control and Prevention: Quality of Life of Black Breast Cancer Survivors</a> </li></ul>

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05087095

Telehealth CALM Therapy for People with Brain Metastasis and Depression or Anxiety

Managing Distress in Malignant Brain Cancer Scientific Title

Purpose

To study if telehealth CALM therapy decreases symptoms of depression or anxiety.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and experiencing depression or anxiety. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Telehealth CALM therapy, 6 sessions over 3 months</li> <li class="seamTextUnorderedListItem">3 questionnaires over 6 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 questionnaires over 6 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Managing Cancer and Living Meaningfully (CALM) therapy is designed to decrease symptoms of depression and anxiety for people with cancer.</li> <li class="seamTextUnorderedListItem">If you are in Group 1, you will receive CALM therapy virtually through telehealth.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05087095' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>